Cover
Cover - shares | 9 Months Ended | |
Dec. 31, 2021 | Feb. 02, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Dec. 31, 2021 | |
Document Transition Report | false | |
Entity File Number | 000-55832 | |
Entity Registrant Name | Transphorm, Inc. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 82-1858829 | |
Entity Address, Address Line One | 75 Castilian Drive | |
Entity Address, City or Town | Goleta, | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 93117 | |
City Area Code | 805 | |
Local Phone Number | 456-1300 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 53,340,958 | |
Entity Central Index Key | 0001715768 | |
Document Fiscal Year Focus | 2022 | |
Current Fiscal Year End Date | --03-31 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2021 | Mar. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 40,467 | $ 9,500 |
Restricted cash | 500 | 0 |
Accounts receivable, net, including related parties | 2,489 | 1,618 |
Inventory | 5,956 | 2,223 |
Prepaid expenses and other current assets | 1,249 | 953 |
Total current assets | 50,661 | 14,294 |
Property and equipment, net | 1,897 | 1,360 |
Goodwill | 1,250 | 1,302 |
Intangible assets, net | 691 | 914 |
Investment in joint venture | 61 | 0 |
Other assets | 282 | 274 |
Total assets | 54,842 | 18,144 |
Current liabilities: | ||
Accounts payable and accrued expenses | 4,749 | 3,140 |
Deferred revenue | 267 | 505 |
Development loan | 0 | 10,000 |
Revolving credit facility, including accrued interest | 368 | 10,150 |
Unfunded commitment to joint venture | 0 | 1,866 |
Accrued payroll and benefits | 1,239 | 1,410 |
Total current liabilities | 6,623 | 27,071 |
Revolving credit facility | 12,000 | 0 |
Promissory note | 0 | 16,128 |
Total liabilities | 18,623 | 43,199 |
Commitments and contingencies (Note 8) | ||
Common stock, shares authorized (in shares) | 750,000,000 | 750,000,000 |
Stockholders’ equity (deficit): | ||
Common stock, $0.0001 par value; 750,000,000 shares authorized as of December 31, 2021 and March 31, 2021, and 53,066,922 and 40,531,996 shares issued and outstanding as of December 31, 2021 and March 31, 2021, respectively | $ 5 | $ 4 |
Additional paid-in capital | 210,841 | 144,201 |
Accumulated deficit | (173,639) | (168,403) |
Accumulated other comprehensive loss | (988) | (857) |
Total stockholders’ equity (deficit) | 36,219 | (25,055) |
Total liabilities and stockholders’ equity (deficit) | $ 54,842 | $ 18,144 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2021 | Mar. 31, 2021 | Feb. 12, 2020 | Feb. 11, 2020 | Dec. 31, 2019 |
Common stock, par value (in usd per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||
Common stock, shares authorized (in shares) | 750,000,000 | 750,000,000 | |||
Common stock, shares issued (in shares) | 53,066,922 | 40,531,996 | 4,171,571 | 50,325,662 | |
Common stock, shares outstanding (in shares) | 53,066,922 | 40,531,996 | 4,171,571 | 50,325,662 | |
Common Stock | |||||
Common stock, shares authorized (in shares) | 750,000,000 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | ||||
Revenue, net, including related parties (Note 11) | $ 4,604 | $ 2,013 | $ 19,123 | $ 10,271 |
Operating expenses: | ||||
Cost of goods sold | 3,935 | 1,936 | 8,741 | 5,227 |
Research and development | 1,609 | 1,453 | 5,023 | 4,118 |
Sales and marketing | 976 | 581 | 2,488 | 1,656 |
General and administrative | 2,852 | 2,490 | 8,309 | 7,236 |
Total operating expenses | 9,372 | 6,460 | 24,561 | 18,237 |
Loss from operations | (4,768) | (4,447) | (5,438) | (7,966) |
Interest expense | 187 | 191 | 611 | 571 |
Loss in joint venture | 712 | 1,618 | 3,294 | 5,417 |
Changes in fair value of promissory note | 0 | (973) | (605) | 1,394 |
Other income, net | (1,503) | (571) | (3,502) | (1,626) |
Loss before tax expense | (4,164) | (4,712) | (5,236) | (13,722) |
Tax expense | 0 | 0 | 0 | 0 |
Net Income (Loss) Attributable to Parent, Total | $ (4,164) | $ (4,712) | $ (5,236) | $ (13,722) |
Net loss per share - basic (in usd per share) | $ (0.08) | $ (0.13) | $ (0.12) | $ (0.38) |
Net loss per share - diluted (in usd per share) | $ (0.08) | $ (0.13) | $ (0.12) | $ (0.38) |
Weighted average common shares outstanding - basic (in shares) | 49,147,630 | 35,719,749 | 43,671,321 | 35,338,132 |
Weighted average common shares outstanding - diluted (in shares) | 49,147,630 | 35,719,749 | 43,671,321 | 35,338,132 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | |
Statement of Comprehensive Income [Abstract] | ||||
Net loss | $ (4,164) | $ (4,712) | $ (5,236) | $ (13,722) |
Other comprehensive loss, net of tax: | ||||
Foreign currency translation adjustments | (70) | (7) | (131) | (18) |
Other comprehensive loss, net of tax | (70) | (7) | (131) | (18) |
Comprehensive loss | $ (4,234) | $ (4,719) | $ (5,367) | $ (13,740) |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) (unaudited) - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss |
Beginning balance (in shares) at Feb. 11, 2020 | 50,325,662 | ||||
Ending balance (in shares) at Feb. 12, 2020 | 4,171,571 | ||||
Beginning balance (in shares) at Mar. 31, 2020 | 35,135,520 | ||||
Beginning balance at Mar. 31, 2020 | $ (21,169) | $ 4 | $ 127,683 | $ (148,102) | $ (754) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Stock options exercised (in shares) | 3,475 | 3,475 | |||
Stock options exercised | $ 14 | 14 | |||
Restricted stock awards issued (in shares) | 139,501 | ||||
Issuance of common stock (in shares) | 5,000,000 | ||||
Issuance of common stock (Note 9) | $ 13,646 | 13,646 | |||
Stock-based compensation | 1,393 | 1,393 | |||
Other comprehensive loss | (18) | (18) | |||
Net loss | (13,722) | (13,722) | |||
Ending balance (in shares) at Dec. 31, 2020 | 40,278,496 | ||||
Ending balance at Dec. 31, 2020 | (19,856) | $ 4 | 142,736 | (161,824) | (772) |
Beginning balance (in shares) at Sep. 30, 2020 | 35,266,496 | ||||
Beginning balance at Sep. 30, 2020 | $ (29,488) | $ 4 | 128,385 | (157,112) | (765) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Stock options exercised (in shares) | 0 | ||||
Restricted stock awards issued (in shares) | 12,000 | ||||
Issuance of common stock (in shares) | 5,000,000 | ||||
Issuance of common stock (Note 9) | $ 13,646 | 13,646 | |||
Stock-based compensation | 705 | 705 | |||
Other comprehensive loss | (7) | (7) | |||
Net loss | (4,712) | (4,712) | |||
Ending balance (in shares) at Dec. 31, 2020 | 40,278,496 | ||||
Ending balance at Dec. 31, 2020 | $ (19,856) | $ 4 | 142,736 | (161,824) | (772) |
Beginning balance (in shares) at Mar. 31, 2021 | 40,531,996 | 40,531,996 | |||
Beginning balance at Mar. 31, 2021 | $ (25,055) | $ 4 | 144,201 | (168,403) | (857) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Stock options exercised (in shares) | 31,925 | 31,925 | |||
Stock options exercised | $ 134 | 134 | |||
Vesting of restricted stock units (in shares) | 12,750 | ||||
Issuance of common stock (in shares) | 9,370,251 | ||||
Issuance of common stock (Note 9) | 50,273 | $ 1 | 50,272 | ||
Conversion of promissory note (Note9) (in shares) | 3,120,000 | ||||
Conversion of promissory note (Note 9) | 14,378 | 14,378 | |||
Stock-based compensation | 1,856 | 1,856 | |||
Other comprehensive loss | (131) | (131) | |||
Net loss | $ (5,236) | (5,236) | |||
Ending balance (in shares) at Dec. 31, 2021 | 53,066,922 | 53,066,922 | |||
Ending balance at Dec. 31, 2021 | $ 36,219 | $ 5 | 210,841 | (173,639) | (988) |
Beginning balance (in shares) at Sep. 30, 2021 | 41,664,020 | ||||
Beginning balance at Sep. 30, 2021 | $ (19,546) | $ 4 | 150,843 | (169,475) | (918) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Stock options exercised (in shares) | 0 | ||||
Vesting of restricted stock units (in shares) | 9,750 | ||||
Issuance of common stock (in shares) | 8,273,152 | ||||
Issuance of common stock (Note 9) | $ 44,773 | $ 1 | 44,772 | ||
Conversion of promissory note (Note9) (in shares) | 3,120,000 | ||||
Conversion of promissory note (Note 9) | 14,378 | 14,378 | |||
Stock-based compensation | 848 | 848 | |||
Other comprehensive loss | (70) | (70) | |||
Net loss | $ (4,164) | (4,164) | |||
Ending balance (in shares) at Dec. 31, 2021 | 53,066,922 | 53,066,922 | |||
Ending balance at Dec. 31, 2021 | $ 36,219 | $ 5 | $ 210,841 | $ (173,639) | $ (988) |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands | 9 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Cash flows from operating activities: | ||
Net loss | $ (5,236) | $ (13,722) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Inventory write-off | 202 | 266 |
Depreciation and amortization | 621 | 599 |
Provision for doubtful accounts | 0 | 110 |
Licensing revenue from a related party | (8,000) | (5,000) |
Stock-based compensation | 1,856 | 1,393 |
Interest cost | 295 | 571 |
Gain on promissory note conversion | (1,222) | 0 |
Loss in joint venture | 1,839 | 5,417 |
Changes in fair value of promissory note | (605) | 1,394 |
Changes in operating assets and liabilities: | ||
Accounts receivable | (871) | 423 |
Inventory | (3,935) | (808) |
Prepaid expenses and other current assets | 204 | 320 |
Other assets | (8) | 197 |
Accounts payable and accrued expenses | 1,359 | 63 |
Deferred revenue | (238) | 674 |
Accrued payroll and benefits | (171) | 139 |
Net cash used in operating activities | (13,910) | (7,964) |
Cash flows from investing activities: | ||
Purchases of property and equipment | (690) | (58) |
Investment in joint venture | (3,765) | (5,800) |
Net cash used in investing activities | (4,455) | (5,858) |
Cash flows from financing activities: | ||
Proceeds from stock option exercise | 134 | 14 |
Proceeds from issuance of common stock, net | 49,773 | 13,646 |
Net cash provided by financing activities | 49,907 | 13,660 |
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | (75) | 208 |
Net increase in cash, cash equivalents and restricted cash | 31,467 | 46 |
Cash, cash equivalents and restricted cash at beginning of period | 9,500 | 14,648 |
Cash, cash equivalents and restricted cash at end of period | 40,967 | 14,694 |
Supplemental disclosures of cash flow information: | ||
Interest expense paid | 316 | 915 |
Supplemental non-cash investing activity: | ||
Equipment purchases | 250 | 0 |
Supplemental non-cash financing activity: | ||
Issuance of shares in connection with a service contract | 500 | 0 |
Development loan reduction related to licensing revenue | 8,000 | 5,000 |
Conversion of promissory note | $ 15,600 | $ 0 |
Business and Basis of Presentat
Business and Basis of Presentation | 9 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Business and Basis of Presentation | Business and Basis of Presentation Transphorm, Inc. (“Parent”) develops gallium nitride (“GaN”) semiconductor components used in power conversion and is headquartered in Goleta, California. Parent’s wholly owned-subsidiary, Transphorm Technology, Inc. (“Transphorm Technology”), was incorporated in the State of Delaware on February 22, 2007. Throughout these notes, “the Company,” “Transphorm,” “we,” “us” and “our” refer to Parent and its direct and indirect wholly-owned subsidiaries. Transphorm Technology and its subsidiaries hold all material assets and conduct all business activities and operations of the Company. Transphorm Technology’s activities to date have been primarily performing research and development, establishing manufacturing infrastructure, market sampling, product launch, hiring personnel, and raising capital to support and expand these activities. Transphorm Japan, Inc. was established in Japan in February 2014 to secure Transphorm’s production capacity and establish a direct presence in Asian markets. Transphorm Aizu, Inc. was established in Japan to manage the financial transactions around Aizu Fujitsu Semiconductor Wafer Solution Limited, Transphorm’s non-controlling joint venture wafer fabrication facility located in Aizu Wakamatsu, Japan (“Aizu”). Transphorm Japan Epi, Inc. was established in Japan in 2019 to enable the operational capacity of the reactors held in Aizu. In management’s opinion, the accompanying unaudited condensed consolidated financial statements of Transphorm reflect all adjustments of a normal and recurring nature that are necessary for a fair presentation of the results for the interim period ended December 31, 2021, but are not necessarily indicative of the results that will be reported for the entire year or any other interim period. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with Accounting Principles Generally Accepted in the United States of America (“GAAP”) have been condensed or omitted. The aforementioned unaudited condensed consolidated financial statements are prepared in conformity with GAAP and in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission. The interim information should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Transition Report on Form 10-K for the transition period from January 1, 2021 to March 31, 2021. The consolidated balance sheet as of March 31, 2021 is derived from those audited financial statements. Change in Fiscal Year End On April 20, 2021, we changed our fiscal year from the period beginning on January 1 and ending on December 31 to the period beginning on April 1 and ending on March 31 of each year, effective immediately. Accordingly, we filed a Transition Report on Form 10-K to include audited consolidated financial information for the transition period from January 1, 2021 through March 31, 2021. Reverse Merger On February 12, 2020, our wholly-owned subsidiary, Peninsula Acquisition Sub, Inc., a corporation formed in the State of Delaware (“Acquisition Sub”), merged with and into Transphorm Technology (formerly known as Transphorm, Inc.), the corporate existence of Acquisition Sub ceased, and Transphorm Technology became our wholly-owned subsidiary (such transaction, the “Merger”). As a result of the Merger, we acquired the business of Transphorm Technology. The Merger was effective as of February 12, 2020, upon the filing of a certificate of merger with the Secretary of State of the State of Delaware. Immediately after completion of the Merger, we adopted Transphorm Technology’s former company name, “Transphorm, Inc.”, as our company name. The Merger was treated as a recapitalization and reverse acquisition for financial reporting purposes, and Transphorm Technology is considered the acquirer for accounting purposes. As a result of the Merger and the change in our business and operations, a discussion of the past financial results of our predecessor, Peninsula Acquisition Corporation, is not pertinent, and under applicable accounting principles, the historical financial results of Transphorm Technology, the accounting acquirer, prior to the Merger are considered our historical financial results. At the effective time of the Merger, (i) each share of Transphorm Technology’s common stock issued and outstanding immediately prior to the closing of the Merger was converted into the right to receive (a) 0.08289152527 shares of our common stock (in the case of shares held by accredited investors) or (b) $4.00 multiplied by 0.08289152527 (in the case of shares held by unaccredited investors), with the actual number of shares of our common stock issued to the former holders of Transphorm Technology’s common stock equal to 4,171,571, (ii) 51,680,254 shares of Transphorm Technology’s Series 1 preferred stock issued and outstanding immediately prior to the closing of the Merger were converted into 12,433,953 shares of our common stock, (iii) 38,760,190 shares of Transphorm Technology’s Series 2 preferred stock issued and outstanding immediately prior to the closing of the Merger were converted into 7,499,996 shares of our common stock, and (iv) 31,850,304 shares of Transphorm Technology’s Series 3 preferred stock issued and outstanding immediately prior to the closing of the Merger were converted into 4,000,000 shares of our common stock. As a result, 28,105,520 shares of our common stock were issued to the former holders of Transphorm Technology’s issued and outstanding capital stock after adjustments due to rounding for fractional shares. Immediately prior to the effective time of the Merger, an aggregate of 682,699 shares of our common stock, owned by the stockholders of Peninsula Acquisition Corporation prior to the Merger, were forfeited and cancelled. In addition, pursuant to the Merger Agreement, (i) options to purchase 29,703,285 shares of Transphorm Technology’s common stock issued and outstanding immediately prior to the closing of the Merger under Transphorm Technology’s 2007 Stock Plan (the “2007 Plan”) and 2015 Equity Incentive Plan (the “2015 Plan”) were assumed and converted into options to purchase 2,461,923 shares of our common stock, (ii) warrants to purchase 186,535 shares of Transphorm Technology’s common stock issued and outstanding immediately prior to the closing of the Merger were assumed, amended and converted into warrants to purchase 15,461 shares of our common stock, and (iii) Transphorm Technology’s outstanding convertible promissory note was amended to be convertible at the option of the holder, into shares of our common stock at a conversion price of $5.12 per share. On October 4, 2021, the promissory note of $15.6 million, consisting of an outstanding principal amount of $15.0 million plus accrued but unpaid interest of $600 thousand, was further amended to reduce the conversion price from $5.12 per share to $5.00 per share and converted into an aggregate of 3,120,000 shares of our common stock. See Note 3 - Fair Value Measurements, Note 6 - Debts and Note 9 - Stockholders’ Equity (Deficit). All per share and share amounts for all periods presented have been retroactively adjusted to reflect the effect of the Merger. Liquidity and Capital Resources The Company’s ability to sustain operations is dependent mainly on its ability to successfully market and sell its products and through additional financings until profitability with positive cash flows are achieved. The Company currently incurs and historically has incurred losses from operations and expects to do so in the foreseeable future. The Company has sustained recurring losses and negative cash flows from operations which previously raised substantial doubt about the Company’s ability to continue as a going concern. During the nine months ended December 31, 2021, the Company used $13.9 million of cash in operations. Although the Company expects to continue to incur losses and negative cash flows from operating activities, during the nine months ended December 31, 2021, the Company raised gross proceeds of $50.9 million from private placements. Consequently, the Company has sufficient resources to fund its operations for the next twelve months from the date of this filing, and therefore, the substantial doubt about the Company’s ability to continue as a going concern has been alleviated. The Company may need to continue to raise additional capital to finance its losses and negative cash flows from operations beyond the next twelve months and may continue to be dependent on additional capital raises. Impact of COVID-19 on Our Business The COVID-19 pandemic has adversely disrupted and will further disrupt the operations at certain of our customers, partners, suppliers and other third-party providers for an uncertain period of time, including as a result of travel restrictions, adverse effects on budget planning processes, business deterioration, and/or business shutdowns, all of which has impacted our business and results of operations. Some of our customers have experienced delays in their internal development programs and design cycles with our GaN products due to the effects of COVID-19, which have led to postponements of their orders of our products and postponements of determinations that our products will be used in their designs for new products under development with corresponding delays in their market introduction and our revenues. The future impact of COVID-19 cannot be predicted with certainty and may make it more difficult or preclude us from raising additional capital, increase our costs of capital and otherwise adversely affect our business, results of operations, financial condition and liquidity. Significant Accounting Policies Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Parent and its wholly-owned subsidiaries, Transphorm Technology, Transphorm Japan, Inc., Transphorm Japan Epi, Inc. and Transphorm Aizu, Inc. Upon consolidation, all significant intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management bases its estimates and assumptions on historical experience, knowledge of current conditions, and its belief of what could occur in the future, given available information. Actual results could differ from those estimates, and such differences could be material to the consolidated financial statements. Estimates are used for, but not limited to, the determinations of fair value of stock awards and promissory notes, accrual of liabilities, revenue recognition, inventory reserve, and useful lives for property and equipment. Cash, Cash Equivalents and Restricted Cash The Company considers all highly-liquid investments with original maturities of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents consist principally of bank deposits and money market funds. Restricted cash of $575 thousand as of December 31, 2021 consists of $500 thousand of cash in current asset and $75 thousand of long-term deposit in other assets. Restricted cash of $75 thousand as of March 31, 2021 consists of long-term deposit in other assets. Foreign Currency Risk The Company is exposed to foreign currency risk due to its operations in Japan (Yen). Assets and liabilities of the operations are re-measured into U.S. currency at exchange rates in effect at the balance sheet dates through the consolidated statements of comprehensive income. Gains or losses resulting from foreign currency transactions are re-measured using the rates on the dates on which those elements are recognized during the period and are included in other income or expense in the consolidated statements of operations. The differences between the exchange rates used for conversion and at the period end on the cash provided/(used in) are the amounts to be presented on the consolidated cash flow statement as effect of foreign exchange rate change on cash, cash equivalents and restricted cash. As of December 31, 2021 and March 31, 2021, the Company had foreign cash and cash equivalents of $65 thousand and $444 thousand, respectively, which represented 0.2 percent and 4.7 percent, respectively, of total cash and cash equivalents. Concentrations of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company is exposed to credit risk in the event of default by the financial institution holding its cash. The Company’s investment policy restricts investments to high-quality investments and limits the amounts invested with any one issuer, industry or geographic area. Risks associated with cash holdings in excess of insured limits are mitigated by banking with high-quality institutions. To date, the Company has not experienced any significant losses on its cash and cash equivalents. The Company periodically evaluates the relative credit standing of these financial institutions. The Company is subject to risks common in the power conversion components industry, including, but not limited to, technological obsolescence, dependence on key personnel, market acceptance of its products, the successful protection of its proprietary technologies, compliance with government regulations, and the possibility of not being able to obtain additional financing when needed. Comprehensive Loss Comprehensive loss is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) includes the impact of foreign currency translation adjustments. Accounts Receivable Accounts receivable are analyzed and allowances for uncollectible accounts are recorded, as required. Provisions for uncollectible accounts, if any, are recorded as bad debt expense and included in general and administrative expenses in the accompanying consolidated statements of operations. The process for determining the appropriate level of allowances for doubtful accounts involves judgment, and the Company considers such factors as the age of the underlying receivables, historical and projected collection trends, the composition of outstanding receivables, current economic conditions and regulatory changes. An account is fully reserved when reasonable collection efforts have been unsuccessful and it is probable that the receivable will not be recovered. Provision for doubtful accounts amounted to $0 for the three months ended December 31, 2021 and recovery of doubtful accounts amounted to $36 thousand for the three months ended December 31, 2020. Provision for doubtful accounts amounted to $0 and $110 thousand for the nine months ended December 31, 2021 and 2020, respectively. Inventory Inventory is stated at the lower of cost (first-in, first-out method) or net realizable value. The Company periodically reviews the value of items in inventory and records write-downs or write-offs based on its assessment of slow moving or obsolete inventory. The Company maintains an inventory reserve for obsolete inventory and generally makes inventory value adjustments against the inventory reserve. Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is determined using the straight-line method over the estimated useful lives of the respective assets, generally ranging from three The Company evaluates the carrying amount of its property and equipment whenever events or changes in circumstances indicate that the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of an asset or asset group and its eventual disposition are less than the carrying amount of the asset or asset group. To date, there have been no such impairment losses. Goodwill Goodwill arose for the acquisition of a business in February 2014 based in Japan and was accounted for as the purchase of a business. Goodwill generated from business combinations and deemed to have indefinite lives are not subject to amortization and instead are tested for impairment at least annually in December unless certain events occur or circumstances change. Goodwill represents the excess of the purchase price over the fair value of the net assets and other identifiable intangible assets acquired. We test for goodwill impairment annually, March 31, or earlier if events or changes in circumstances indicate goodwill might possibly be impaired. Impairment exists when the carrying value of the goodwill exceeds its implied fair value. An impairment loss would be recognized in an amount equal to that excess as a charge to operations in the unaudited condensed consolidated statements of operations. For the three and nine months ended December 31, 2021 and 2020, no impairment charge was recorded related to goodwill. Intangible Assets Intangible assets that are not considered to have an indefinite useful life are amortized over their estimated useful lives, which generally range from three If it is determined that the carrying values might not be recoverable based upon the existence of one or more indicators of impairment, the Company performs a test for recoverability using various methodologies, such as the income approach or cost approach, to determine the fair value of intangible assets depending upon the nature of the assets. If assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds their respective fair values. For the three and nine months ended December 31, 2021 and 2020, no impairment charges were recorded related to intangible assets. Revenue Recognition The Company derives its revenues from sales of high-powered GaN-based products manufactured utilizing the Company’s proprietary and patented epiwafer technology and wafer fabrication and other assembly processes, sales of GaN epiwafers for the radio frequency (“RF”) and power markets, and sales of licenses to use such patented proprietary technology, as well as enabling EPI wafer growth services and products to our strategic partners. Revenues are recognized when control of these products or licenses are transferred to the Company’s customers in an amount that reflects the consideration it expects to be entitled to in exchange for those products and licenses. Sales and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. Incidental items that are immaterial in the context of the contract are recognized as expense. The Company does not have any significant financing components associated with its revenue contracts, as payment is received at or shortly after the point of sale. Disaggregation of Revenue from Contracts with Customers Revenue consists of licensing revenue, government contract revenue from our contract with the U.S. Navy and product sales, with applicable performance obligations satisfied at a point in time. Products are sold to distributors and end-users in various sectors such as, but not limited to, the automotive, gaming, industrial, IT, and consumer products industries. As part of the multi-element commercial arrangement executed with Nexperia on April 4, 2018 (see Note 2 - Nexperia Arrangement), the Company agreed to grant Nexperia the perpetual exclusive right to use the Company’s existing Gen-3 manufacturing process technology. License fees are received upon satisfaction of contractual milestones and recognized upon delivery of the perpetual license or transferred technology without any remaining performance obligations. The Company recognized $0 and $8.0 million of licensing revenue for the three and nine months ended December 31, 2021, respectively, and $0 and $5.0 million of licensing revenue for the three and nine months ended December 31, 2020, respectively. In December 2020, the Company entered into a cooperation and development agreement with Yaskawa Electric Corporation (“Yaskawa”), pursuant to which Yaskawa agreed to provide $4.0 million over approximately three years to fund development activities related to industrial power conversion applications, with an initial focus on servo motor drive applications. Yaskawa provided payments of $1.0 million and $750 thousand of this $4.0 million commitment in December 2020 and July 2021, respectively. The Company evaluated and concluded that the deliverables are the same and nature of the services to be provided to Yaskawa will be consistent over the period of approximately three years. Accordingly, the Company recognized $333 thousand as revenue in each of the three months ended December 31, 2020, March 31, 2021 and June 30, 2021 and recognized $375 thousand as revenue in each of the three months ended September 30, 2021 and December 31, 2021. Government contract revenues are principally generated under research and development contracts. Contract revenues are derived primarily from research contracts with agencies of the U.S. government. We believe credit risk related to accounts receivable arising from such contracts is minimal. These contracts may include cost-plus fixed fee and fixed price terms. All payments to us for work performed on contracts with agencies of the U.S. government are subject to adjustment upon audit by the Defense Contract Audit Agency. The contract expires March and June 2022 and the Company is working on an extension. The Company received new government authorized rates for billing purposes which allowed for retroactive application since inception. The cumulative impact of this rate change as of December 31, 2021 was $423 thousand, of which $(83) thousand and $505 thousand were recorded in the three months ended March 31, 2021 and September 30, 2020, respectively. The Company will use the new approved rates on a go-forward basis. Performance Obligations For performance obligations related to the sale of products, control transfers to the customer at a point in time. The Company’s principal terms of sale are free on board shipping or destination and the Company transfers control and records revenue for product sales upon shipment or delivery to the customer, respectively. For performance obligations related to the licensing of patented technology in perpetuity, control also transfers to the customer at a point in time. The Company transfers control and records revenue for licensing fees once the Company has (i) provided or otherwise makes available the patented technology to the customer and (ii) the customer is able to use and benefit from the patented technology. Variable Consideration The nature of the Company’s arrangement with Nexperia gives rise to variable consideration in the form of milestone and royalty payments. The royalties qualify for the sales and usage-based royalty exception, as the license of intellectual property is the predominant item to which the royalty relates and are recognized upon the subsequent sale occurring. The variable amounts are received upon satisfaction of contractually agreed upon development targets and sales volume. Research and Development The Company is a party to research grant contracts with the U.S. government for which the Company is reimbursed for specified costs incurred for its research projects. These projects include energy saving initiatives for which the U.S. government offers reimbursement funds. Such reimbursements are recorded as an offset to research and development expenses when the related qualified research and development expenses are incurred. Reimbursable costs are recognized in the same period the costs are incurred up to the limit of approved funding amounts on qualified expenses. Grant reimbursement of $80 thousand and $47 thousand was recorded as an offset to research and development expense for the three months ended December 31, 2021 and 2020, respectively. Grant reimbursement of $151 thousand and $353 thousand was recorded as an offset to research and development expense for the nine months ended December 31, 2021 and 2020, respectively. Stock-Based Compensation All share-based payments, including grants of stock options, restricted stock awards (“RSAs”) and restricted stock units (“RSUs”), are measured at the fair value of the share-based awards on the grant date and recognized over their respective vesting periods, which is generally one RSUs are measured using the fair market value of the stock price at grant date. The Company recognizes the fair value of share-based payments as compensation expense for all expected-to-vest stock-based awards over the vesting period of the award using the straight-line attribution or graded vesting method provided that the amount of compensation cost recognized at any date is no less than the portion of the grant-date fair value of the award that is vested at that date. The Black-Scholes-Merton option pricing model requires inputs such as the fair value of common stock on date of grant, expected term, expected volatility, dividend yield, and risk-free interest rate. Further, the forfeiture rate also affects the amount of aggregate compensation expense. These inputs are subjective and generally require significant analysis and judgment to develop. Volatility data is obtained from a study of publicly traded industry peer companies. The forfeiture rate is derived primarily from the Company’s historical data, and the risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues commensurate with the expected term. Management generally uses the simplified method to calculate the expected term for employee grants as the Company has limited historical exercise data or alternative information to reasonably estimate an expected term assumption. The simplified method assumes that all options will be exercised midway between the weighted average vesting date and the contractual term of the option. Stock-based compensation expense recognized in the Company’s unaudited condensed consolidated financial statements is based on awards that are expected to vest. These expense amounts have been reduced by using an estimated forfeiture rate. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company evaluates the assumptions used to estimate forfeitures annually in connection with the recognition of stock-based compensation expense. Income (Loss) Per Share Basic income (loss) per share is calculated by dividing net income (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is calculated by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares outstanding plus potential dilutive common shares outstanding during the period. Potential dilutive securities, comprised of stock warrants, restricted stock units and stock options, are not reflected in diluted income (loss) per share because such shares are anti–dilutive. Dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. For the three and nine months ended December 31, 2021, there were 6,947,976 shares, consisting of 2,957,904 stock options, 1,248,007 restricted stock units and 2,742,065 stock warrants, that were not included in the computation of diluted income per share because their effect would be anti-dilutive. For the three and nine months ended December 31, 2020, there were 3,285,058 shares, consisting of 2,320,318 stock options, 805,325 restricted stock units and 159,415 stock warrants, that were not included in the computation of diluted loss per share because their effect would be anti-dilutive. Fair Value Measurement Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying values of the Company’s financial instruments such as cash equivalents, accounts receivable, revolving credit facility, accounts payable and accrued liabilities approximate fair values due to the short-term nature of these items. Income Taxes The Company accounts for income taxes in accordance with Accounting Standards Codification (“ASC”) 740, Income Taxes (“ASC 740”). ASC 740 prescribes the use of the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and the tax basis of assets and liabilities and are measured using the enacted statutory tax rates in effect at the balance sheet date. The Company records a valuation allowance to reduce its deferred tax assets when uncertainty regarding their realizability exists. Equity Method Investments The Company uses the equity method to account for investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. The Company's proportionate share of the net income or loss of these companies is included in consolidated net loss. Judgments regarding the level of influence over each equity method investment include consideration of key factors such as the Company's ownership interest, representation on the board of directors or other management body and participation in policy-making decisions. Segment Reporting The Company’s operations and its financial performance is evaluated on a consolidated basis by the chief operating decision maker. The Company’s chief operating decision maker is the Parent’s Chief Executive Officer. Accordingly, the Company considers all of its operations to be aggregated in one reportable operating segment. For the three months ended December 31, 2021, total revenue was $4.6 million, of which $4.6 million was from U.S. operations and $9 thousand was from Japan operations. For the three months ended December 31, 2020, total revenue was $2.0 million, of which $1.6 million was from U.S. operations and $392 thousand was from Japan operations. For the nine months ended December 31, 2021, total revenue was $19.1 million, of which $18.6 million was from U.S. operations and $506 thousand was from Japan operations. For the nine months ended December 31, 2020, total revenue was $10.3 million, of which $9.6 million was from U.S. operations and $702 thousand was from Japan operations. Recently Issued Accounting Standards under Evaluation Debt - In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to address the complexity in accounting for certain financial instruments with characteristics of liabilities and equity. Amongst other provisions, the amendments in this ASU significantly change the guidance on the issuer’s accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity’s own equity such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment. Refer to our white paper, Accounting simplifications for convertible instruments and warrants, for additional information. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact of this new standard on its consolidated financial statements and the adoption is not expected to have a significant impact on the consolidated financial statements. Leases - In June 2020, the FASB issued ASU 2020-05, which amends the effective dates of the FASB’s standards on leasing (ASC 842) to give immediate relief to certain entities as a result of the widespread adverse economic effects and business disruptions caused by the COVID-19 pandemic. In February 2016, the FASB issued ASU 2016-02, Leases , which, for operating leases, requires the lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, on its balance sheet. The guidance also requires a lessee to recogn |
Nexperia Arrangement
Nexperia Arrangement | 9 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Nexperia Arrangement | Nexperia Arrangement Nexperia Transaction On April 4, 2018, the Company entered into a multi-element commercial arrangement with Nexperia B.V. (“Nexperia”) to obtain financing in exchange for the sale of equity instruments and performing certain technology and product development activities for Nexperia (collectively, the “Collaboration Arrangement”). Nexperia specializes in designing, manufacturing and selling a broad range of small discrete semiconductor devices that utilize components such as those manufactured by the Company. Financing under the Collaboration Arrangement is comprised of the following elements: • $16 million Series 3 preferred stock issuance • $9 million license fee for transfer of the Gen-3 manufacturing process • $5 million development loan, originally maturing March 31, 2020 and subsequently extended to June 30, 2020 intended to pre-fund the Gen-4 (Tranche A) technology development (the “Tranche A Loan”) • $10 million development loan maturing March 31, 2021 intended to pre-fund the Gen-5 and 1200V technology development (the “Tranche B Loan”) • $10 million revolving loan (the “Tranche C Loan”) The Company has to use the funds to operate the business in a manner consistent with or reasonably related to those business activities as carried out on or prior to April 4, 2018, the effective date of Collaboration Arrangement. In addition to the multiple elements outlined above, the Company and Nexperia entered into a Supply Agreement requiring that the Company be Nexperia’s primary supplier of specified components until June 30, 2020 on a best efforts basis. By entering into this Collaboration Arrangement, Nexperia gained access to technology that allows for production of high power semiconductors for use in electric vehicles. Further, Nexperia obtained an exclusive license and market access to automotive customers outside of Japan and a sole license (non-exclusive of the Company), as well as market access to customers in other parts of the power market. Nexperia has a lien on certain of the Company’s U.S. patents not relating to metal organic chemical vapor deposition (“MOCVD”) or epiwafer technology, per the agreement. On March 31, 2019, the Company executed Amendment No. 1 to the Loan and Security Agreement (the ”LSA”), pursuant to which the Tranche B Loan was bifurcated into the following two separate sub-tranches: • $8 million development loan intended to pre-fund the Gen-5 (Tranche B) technology development (the “Tranche B Loan”) • $2 million development loan intended to pre-fund the 1200V technology development (the “Tranche B-1 Loan” and, together with the Tranche B Loan, the “Tranche B Loans”) On February 7, 2020, Amendment No. 2 to the LSA was executed to acknowledge the then-pending Merger, reaffirm the terms of the loans and confirm the waiver for the late delivery of the Company’s 2018 audited financial statements. On April 8, 2020, Amendment No. 3 to the LSA was executed to extend the maturity of the Tranche A Loan to April 30, 2020. On April 28, 2020, Amendment No. 4 to the LSA was executed to further extend the maturity of the Tranche A Loan to June 30, 2020. All other terms set forth under the original LSA remained unchanged following the amendments. The Tranche A and Tranche B Loans represent pre-funding for Gen-4 (Tranche A), Gen-5 (Tranche B), and 1200V (Tranche B-1) technology development for Nexperia. The specific development activities and associated performance milestones are contained within a Statement of Work (“SoW”) between the Company and Nexperia. The SoW may be modified from time to time based upon mutual business interests. This promise to perform the technology development is a good/service provided to a customer in exchange for consideration in the form of the technology development license fees that offset the Tranche A and Tranche B Loans outstanding. The Development Loans are recognized as a liability equal to the cash proceeds received. In relation to the license fee for the transfer of the Company’s Gen-3 manufacturing process to Nexperia, the Company received $3 million (the first of three tranches) in October 2018, $3 million (the second of three tranches) in April 2019, and $3 million (the third of three tranches) in October 2019. The Company recognized $9.0 million as licensing revenue during 2019 upon the completion of the transfer of the Company’s Gen-3 manufacturing process technology and mutual sign off between Nexperia and the Company. In January 2019, the Company received the $5 million Tranche A Loan. In June 2020, Nexperia agreed that the $5 million Tranche A Loan was permanently satisfied in full in connection with the Company transferring its Gen-4 technology development to Nexperia, at which point the Company recognized $5 million as licensing revenue. In June and July 2019, the Company received the $8 million Tranche B Loan. In December 2019, the Company received the $2 million Tranche B-1 Loan. The Company received the full $10 million Tranche C Loan under the credit facility during the year ended December 31, 2018. See Note 6 - Debts. On March 1, 2021, Amendment No. 5 to the LSA was executed to extend the maturity of the Tranche B loans of $10 million and the Tranche C Loan of $10 million to June 30, 2021 and May 18, 2021, respectively. On May 18, 2021, Amendment No. 6 to the LSA was executed to (1) extend the maturity date for the Tranche C Loans to the earlier of April 4, 2023 and the occurrence of specified change of control events, (2) add Parent as a guarantor of Transphorm Technology’s obligations under the Loan Agreement, and (3) convert the outstanding $2 million Tranche B-1 Loan into a Tranche C-1 Loan, which Tranche C-1 Loan has the same terms and conditions as the existing Tranche C Loan. On May 18, 2021, in addition to Amendment No. 6 to the LSA, the Company entered into a series of agreements with Nexperia, as described below. Strategic Cooperation Agreement The strategic cooperation agreement serves as a framework agreement that describes the numerous agreements between the parties and provides Nexperia with information rights and inspection rights with respect to the Company’s business. Option Agreement The option agreement establishes the parameters pursuant to which Nexperia, in certain limited instances, is permitted to exercise an option (the “Option”) to acquire Transphorm Japan Epi, Inc. (“TJE”), a Japanese subsidiary of the Company through which the Company is engaged in the development, manufacturing and sales of gallium nitride (“GaN”) based epitaxial wafer products. In general, the Option is exercisable upon (1) certain acquisitions of securities or assets of the Company or its subsidiaries by a Competitor (as defined in the option agreement) that results in the Company, directly or indirectly, owning less than a majority of TJE, which acquisition is followed by any material breach (that is not cured within a specified time period) by the Company or a subsidiary of its obligations with respect to epiwafer supply to Nexperia under the Company’s amended and restated supply agreement (the “Supply Agreement”) with Nexperia, or (2) the unilateral termination by the Company of the Supply Agreement. The option agreement also establishes the material terms, including price and timing, for the exercise of the Option by Nexperia. The Option terminates (1) if the Option is not exercised by Nexperia prior to the date on which the option agreement terminates, or (2) on the first to occur of (a) the termination of the option agreement upon written agreement of the parties, (b) the mutual termination or expiration of the Supply Agreement, or (c) the first to occur of (i) two years following the date on which the Company notifies Nexperia of epiwafer qualification of a second source and (ii) April 1, 2028. In connection with the option agreement, the Company has also amended and restated its existing intracompany license agreement with TJE to clarify Nexperia’s rights upon exercise of the Option. Amended and Restated Development and License Agreement The Company entered into an amended and restated development and license agreement (the “DLA”) with Nexperia, pursuant to which the Company agreed to develop and transfer to Nexperia certain manufacturing process technologies to enable Nexperia to manufacture GaN-based products at Nexperia’s facilities. These technologies to be transferred included the Company’s Gen-3, Gen-4 (Tranche A), and Gen-5 (Tranche B) process technologies, but do not include the Company’s Epi Process Technology (as defined in the DLA). Nexperia also agreed to provide funding for the development of such technologies in return for limited exclusivities in automotive and other fields. Nexperia’s rights now include sale of products in the automotive field in Japan along with Transphorm’s rights for sale of products in the automotive field in Japan which remain in place. As per the original agreement, after April 2023, Nexperia’s exclusive rights for sale of products in the automotive field outside of Japan terminate. In addition, the parties have clarified the ability of Nexperia’s customers to use products developed by Nexperia through exercise of its rights under this agreement. Amended and Restated Supply Agreement The Company entered into the Supply Agreement with Nexperia, which sets forth the terms under which Nexperia may purchase epiwafers and processed wafers from the Company, and the Company may purchase processed wafers from Nexperia. The agreement specifies that Nexperia is the Company’s priority customer with respect to epiwafers manufactured by TJE and, accordingly, has preferred utilization of extra capacity, and further specifies procedures to address expansion of the Company’s epiwafer manufacturing capacity and Nexperia’s obligations with respect thereto. The term of the Supply Agreement was extended until December 31, 2025, with automatic one year renewals thereafter, and the Company may not terminate the Supply Agreement while the Option Agreement is in effect. On June 30, 2021, Amendment No. 7 to the LSA was executed to extend the maturity of the Tranche B loans of $8 million to July 16, 2021. On July 16, 2021, Nexperia agreed that the $8 million Tranche B Loan was satisfied in full in connection with the Company transferring its Gen-5 and 1200V technology developments to Nexperia, at which point the Company recognized $8 million as licensing revenue. |
Fair Value Measurements
Fair Value Measurements | 9 Months Ended |
Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements FASB ASC 820, Fair Value Measurements and Disclosures , establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: Level 1 - Unadjusted quoted prices in active markets for identical assets and liabilities. Level 2 - Inputs (other than quoted prices included within Level 1) that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data of substantially the full term of the related assets or liabilities. Level 3 - Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Inputs are unobservable for the asset or liability. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table summarizes the Company’s liabilities measured at fair value as of the dates presented, by level within the fair value hierarchy (in thousands) : Level 1 Level 2 Level 3 December 31, 2021 Promissory note $ — $ — $ — March 31, 2021 Promissory note $ — $ — $ 16,128 The following table includes the changes in fair value of the promissory note which are Level 3 on the fair value hierarchy (in thousands) : April 1, 2021 $ 16,128 Interest expense accrued 77 Increase in fair value (605) Conversion (15,600) December 31, 2021 $ — April 1, 2020 $ 13,885 Interest expense accrued 150 Increase in fair value 2,093 March 31, 2021 $ 16,128 On October 4, 2021, the promissory note of $15.6 million, consisting of an outstanding principal amount of $15.0 million plus accrued but unpaid interest of $600 thousand, was converted into an aggregate of 3,120,000 shares of common stock. See Note 6 - Debts and Note 9 - Stockholders’ Equity (Deficit). The Company recorded interest expense of $3 thousand and $38 thousand for the three months ended December 31, 2021 and 2020, respectively. The Company recorded interest expense of $77 thousand and $113 thousand for the nine months ended December 31, 2021 and 2020, respectively. Fair value of promissory note decreased by $605 thousand for the nine months ended December 31, 2021. Fair value of promissory note decreased by $973 thousand and increased by $1.4 million for the three and nine months ended December 31, 2020, respectively. Level 3 borrowings, which consist of promissory note, are measured and reported at fair value using a Monte Carlo simulation valuation model. The models can include assumptions related to the value of the notes that are based on the estimated timing and amounts of future rounds of financing, including the estimated timing of a change in control of the Company, and estimated market interest rates, which represent significant unobservable inputs. Assumptions used are (1) the Company is worth today what it can generate in future cash to the Company, (2) cash received today is more than an equal amount of cash received in the future, and (3) future cash flows can be reasonably estimated. The following table summarizes assumptions used for fair value of promissory note as of the dates presented: December 31, 2021 March 31, 2021 Stock price — $3.75 Time — 1.5 years Risk-free rate — 0.12% Volatility — 50.6% |
Concentration of Credit Risk an
Concentration of Credit Risk and Significant Customers | 9 Months Ended |
Dec. 31, 2021 | |
Risks and Uncertainties [Abstract] | |
Concentration of Credit Risk and Significant Customers | Concentration of Credit Risk and Significant Customers The Company manages its credit risk associated with exposure to distributors and direct customers on outstanding accounts receivable through the application of credit approvals and other monitoring procedures. Credit sales, which are mainly on credit terms of 30 to 60 days, are only made to customers who meet the Company's credit standards, while sales to new customers or customers with low credit ratings are usually made on an advance payment basis. The Company closely monitors the aging of accounts receivable from its distributors and direct customers, and regularly reviews their financial positions, where available. Significant customers are those that represent 10% or more of revenue or accounts receivable and are set forth in the following table: Accounts Receivable As of December 31, 2021 March 31, 2021 Customer A 15.3% 31.1% Customer B 21.1% 33.9% Customer C 39.7% * Customer D * 10.0% Revenue for the Three Months Ended December 31, Revenue for the Nine Months Ended December 31, 2021 2020 2021 2020 Customer A 10.9% 23.8% 49.8% 62.6% Customer B 21.3% 43.9% 15.7% 26.6% Customer C 41.2% * 16.1% * Customer D * * * * * Less than 10% of total Customer A is a related party and Customer B is a government agency. JCP Capital Management, LLC is a majority stockholder of Customer C. See Note 7 - Investment in AFSW and Note 11 - Related Party Transactions. |
Inventory
Inventory | 9 Months Ended |
Dec. 31, 2021 | |
Inventory Disclosure [Abstract] | |
Inventory | Inventory Inventory consists of the following as of the dates presented (in thousands) : December 31, 2021 March 31, 2021 Raw materials $ 2,423 $ 626 Work in process 2,191 1,054 Finished goods 1,342 543 Total $ 5,956 $ 2,223 An inventory write-off of $8 thousand and $161 thousand was recorded for the three months ended December 31, 2021 and 2020, respectively. An inventory write-off of $202 thousand and $266 thousand was recorded for the nine months ended December 31, 2021 and 2020, respectively. |
Debts
Debts | 9 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
Debts | Debts Development Loans On April 4, 2018, the Company entered into a Loan and Security Agreement (“LSA”) and Development and License Agreement (“DLA”) with Nexperia. The LSA provided for term loans in an aggregate principal amount of up to $15.0 million, which term loans were available in tranches (Tranche A, Tranche B and Tranche B-1) and subject to the satisfaction of specified conditions. The Tranche A Loan of $5.0 million initially was scheduled to mature on the earlier of the date a specified report is required to be delivered under the DLA or March 31, 2020. On April 8, 2020, the maturity of the Tranche A loan was extended to April 30, 2020 and, on April 28, 2020, the maturity of the Tranche A Loan was further extended to June 30, 2020. On June 29, 2020, the Tranche A Loan of $5.0 million was satisfied in full when the Company transferred its Gen-4 technology development to Nexperia. The Tranche B Loan of $8.0 million and Tranche B-1 Loan of $2.0 million mature on the earlier of the date a specified report is required to be delivered under the DLA or March 31, 2021, subject to extension as provided in the LSA. On March 1, 2021, the maturity of the Tranche B Loan of $8.0 million and Tranche B-1 Loan of $2.0 million was extended to June 30, 2021. On May 18, 2021, Tranche B-1 Loan of $2.0 million was converted into a Tranche C-1 Loan, which Tranche C-1 Loan has the same terms and conditions as the existing Tranche C Loan. On June 30, 2021, the maturity of the Tranche B Loan was extended to July 16, 2021. On July 16, 2021, the Tranche B Loan of $8.0 million was satisfied in full when the Company transferred its Gen-5 and 1200V technology developments to Nexperia. See Note 2 - Nexperia Arrangement. As of December 31, 2021, and March 31, 2021, aggregate principal amount of term loans outstanding under the LSA were $0 and $10.0 million, respectively. Revolving Credit Facility The LSA also provided a $10.0 million revolving loan (Tranche C Loan) that was scheduled to mature at the earlier of (i) April 3, 2021, and (ii) the date a Change of Control (as defined in the LSA) of the Company occurs. Interest payable by the Company accrues on the outstanding principal amount of the loans during such period at a rate of 6% per annum. The credit facility is secured against certain of our U.S. patents not relating to MOCVD or epiwafer technology. On March 1, 2021, the maturity of the Tranche C Loan of $10.0 million was extended to May 18, 2021. On May 18, 2021, the maturity of the Tranche C Loan was extended to the earlier of April 4, 2023 and the occurrence of specified change of control events, and $2.0 million Tranche B-1 Loan converted into a Tranche C-1 Loan (the “Tranche C Loans” together with the Tranche C Loan) with the same terms and conditions as the existing Tranche C Loan. See Note 2 - Nexperia Arrangement. The Tranche C Loans are recorded based on principal in the amount of $12.0 million and accrued interest (6% interest per annum). The Company recorded interest expense of $184 thousand and $153 thousand for the three months ended December 31, 2021 and 2020, respectively, and $534 thousand and $458 thousand for the nine months ended December 31, 2021 and 2020, respectively. The Company paid interest expense of $0 and $153 thousand for the three months ended December 31, 2021 and 2020, respectively, and $316 thousand and $915 thousand for the nine months ended December 31, 2021 and 2020, respectively. As of December 31, 2021 and March 31, 2021, the total balance of the revolving credit facility was $12.4 million and $10.2 million, respectively. Promissory Note The Company’s stated value of promissory note obligation as of the dates presented consists of the following (in thousands) : Interest Rate Due Date December 31, 2021 March 31, 2021 Yaskawa Note 1.00% September 2022 $ — $ 15,523 Pursuant to ASC 825-10-15-4, the Company elected to apply the fair value option for the promissory note. As of the dates presented, the Company determined the fair value for the note, as compared to the face value, including accrued interest, as follows (in thousands) : December 31, 2021 March 31, 2021 Yaskawa Note $ — $ 16,128 Fair value of promissory note decreased $605 thousand and increased $1.4 million for the nine months ended December 31, 2021 and 2020, respectively. In October 2017, the Company issued an unsecured subordinated convertible promissory note to Yaskawa (the “Yaskawa Note”) for $15.0 million. The stated interest rate of the Yaskawa Note was 1.0%, and principal plus interest was due on the earlier of September 30, 2022, or the date of the occurrence of an Event of Default, Change of Control or an Initial Public Offering (all terms as defined in the Yaskawa Note). In connection with the Merger, the Yaskawa Note was amended to be convertible at the option of the holder into a maximum of 3,076,171 shares of our common stock at a conversion price of $5.12 per share. During September 2021, the Company offered Yaskawa an option to convert the $15.0 million note, including accrued any unpaid interest of $600 thousand, at $5.00 per share and also receive a warrant to purchase 650,000 shares of common stock at $6.00 per share, exercisable within a three year period. On October 4, 2021, the Company entered into a Note Amendment and Conversion Agreement with Yaskawa to (i) reduce the conversion price of the Yaskawa Note from $5.12 per share to $5.00 per share and (ii) remove the limitation on the maximum number of shares of the Company’s stock that could be issued upon conversion of the Yaskawa Note. Yaskawa simultaneously elected to convert the outstanding principal amount (plus accrued but unpaid interest) under the Yaskawa Note, which as of the effective date of the conversion totaled $15.6 million, into an aggregate of 3,120,000 shares of our common stock. The Company also issued to Yaskawa a warrant to purchase up to 650,000 shares of common stock at an exercise price of $6.00 per share with a term of three years. During the three and nine months ended December 31, 2021, the Company recognized $1.2 million gain, in other income, upon the conversion of the Yaskawa Note. In connection with its promissory note obligation, the Company recorded interest expense of $3 thousand and $38 thousand for the three months ended December 31, 2021 and 2020, respectively, and $77 thousand and $113 thousand for the nine months ended December 31, 2021 and 2020, respectively. In accordance with the terms of the promissory note, interest is added to the principal balance and is reflected in the carrying value on the consolidated balance sheet. As of December 31, 2021 and March 31, 2021, accrued interest on the promissory note was $0 and $523 thousand, respectively. In December 2020, the Company entered into a cooperation and development agreement with Yaskawa, pursuant to which Yaskawa agreed to provide $4.0 million over approximately three years to fund development activities related to industrial power conversion applications, with an initial focus on servo motor drive applications. Yaskawa provided payments of $1.0 million and $750 thousand of this $4.0 million commitment in December 2020 and July 2021, respectively. Accordingly, with respect to the $1.0 million payment, the Company recognized $333 thousand as revenue in each of the three months ended December 31, 2020, March 31, 2021 and June 30, 2021 and, with respect to the $750 thousand payment, the Company recognized $375 thousand as revenue in each of the three months ended September 30, 2021 and December 31, 2021. As of December 31, 2021, the scheduled maturity, including accrued interest, of the Company’s borrowings under the Tranche C Loans was as follows (in thousands) : Year Ending March 31, 2022 $ 368 2023 — 2024 12,000 Total $ 12,368 |
Investment in Aizu Fujitsu Semi
Investment in Aizu Fujitsu Semiconductor Wafer Solution Limited ("AFSW") | 9 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Investment in Aizu Fujitsu Semiconductor Water Solution Limited ("AFSW") | Investment in Aizu Fujitsu Semiconductor Wafer Solution Limited (“AFSW”) Through July 31, 2021, the Company was party to a joint venture agreement (the “JVA”), by and among Aizu Fujitsu Semiconductor Limited, Fujistu Semiconductor Limited (“FSL”), the Company and Transphorm Aizu, Inc. (“Transphorm Aizu”) for the ownership and operations of AFSW. Through July 31, 2021, the Company held a 49% interest in AFSW through Transphorm Aizu, the Company’s wholly-owned subsidiary established in Japan to manage the financial transactions around AFSW. Transphorm Aizu and FSL funded AFSW based on a mutually agreed funding schedule, which was adjusted as agreed upon by both parties during the three months ended September 30, 2021. Any outstanding balances were reviewed upon the conclusion of the JVA effective July 31, 2021 to assess unfunded commitment to joint venture liability. During the nine months ended December 31, 2021, the Company recognized a $1.5 million gain, in other income, upon termination of the JVA and settlement of its obligation. On April 1, 2020, FSL exercised its put option under the JVA and notified us that FSL intended to exit the joint venture by selling its 51% interest in AFSW to us. In December 2020, the Company entered into a joint venture agreement with JCP Capital Management, LLC (controlling party with 75% ownership) to create GaNovation, a joint venture company in Singapore, to engage in the business of distribution, development and supply of GaN products and, upon approval of the regulatory authorities in Japan, to purchase FSL’s and Transphorm’s interests in AFSW. In July 2021, regulatory authorities in Japan approved GaNovation’s purchase of 100% of the interests in AFSW from Transphorm and FSL. On July 20, 2021, Transphorm Aizu entered into a Share Purchase Agreement (the “Purchase Agreement”) with GaNovation, pursuant to which GaNovation agreed to acquire Transphorm’s 49% interest in AFSW from Transphorm Aizu for 1 Japanese Yen. The closing of the Purchase Agreement occurred on August 1, 2021. Following the closing of the Purchase Agreement and other concurrent transactions between GaNovation and FSL, Transphorm, through GaNovation, holds a 25% interest in AFSW (down from the previous 49%). The Company has agreed to use its best efforts to maintain the operations of AFSW until at least August 1, 2022. AFSW manufactures semiconductor products exclusively for its owners under manufacturing agreements at prices estimated to cover the cost of production. AFSW was determined to be a variable interest entity as the equity at risk was not believed to be sufficient. AFSW depends on its owners for any additional cash. The Company extended $3.8 million and $5.8 million to AFSW to fund AFSW’s operations for the nine months ended December 31, 2021 and 2020, respectively. The Company’s known maximum exposure to loss approximated the carrying value of its investment balance, which included the financing. Potential future losses could be higher than the carrying amount of the Company’s investment, as the Company is liable, along with the controlling owner, for other future operating costs or obligations of AFSW. In addition, because Transphorm is currently committed to purchasing GaN wafers and production-related services from AFSW at pre-agreed pricing based upon the Company’s second generation products, the Company may be required to purchase products at a higher cost for its newer generation products. Investment in AFSW was $61 thousand as of December 31, 2021 and unfunded commitment to AFSW was $1.9 million as of March 31, 2021. The Company’s investment activities in AFSW for the periods presented are summarized below (in thousands) : For the Nine Months Ended December 31, 2021 For the Year Ended March 31, 2021 Beginning balance $ (1,866) $ (1,546) Investment 3,765 6,768 Loss (3,294) (6,885) Gain 1,455 — Effect of exchange rate change 1 (203) Ending balance $ 61 $ (1,866) Summarized financial information of AFSW for the periods indicated, as provided by the controlling owner, are as follows (in thousands) : As of December 31, 2021 March 31, 2021 Current assets $ 1,844 $ 932 Long-term assets $ 5,152 $ 5,330 Other current liabilities $ 3,494 $ 2,200 Due to controlling owner $ 3,707 $ 22,354 Due to Transphorm $ 594 $ 13,179 Net deficit $ (799) $ (31,471) For the Three Months Ended December 31, For the Nine Months Ended December 31, 2021 2020 2021 2020 Sales $ 2,262 $ 698 $ 5,957 $ 1,728 Gross loss $ (2,338) $ (2,896) $ (7,094) $ (9,214) Net loss $ (2,848) $ (3,303) $ (9,085) $ (11,057) |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Commitment with a Government Agency In connection with a contract with a government agency, the Company entered into a commitment to acquire equipment and services from vendors totaling $7.4 million, all of which is reimbursable. The contract expires March and June 2022 and the Company is working on an extension. The Company has made total purchases of $7.2 million cumulatively as of December 31, 2021, of which $7.2 million was reimbursed by the government agency as of December 31, 2021. During the three and nine months ended December 31, 2021, the Company made purchases of $119 thousand and $347 thousand, respectively, and the remaining accounts payable to the vendors was $135 thousand as of December 31, 2021. For the three months ended March 31, 2021, the Company made purchases of $270 thousand, of which $124 thousand was in accounts payable as of March 31, 2021. In September 2021, the Company was awarded a $0.9 million contract with a $0.5 million option by a government agency for delivering epiwafer technology. The Company billed and received $2 thousand and $5 thousand for the three and nine months ended December 31, 2021, respectively. Operating Leases The Company leases office and fabrication space in Goleta, California, and office space in Campbell, California and in Japan under noncancelable operating lease agreements. The terms of certain leases provide for escalating rental payments through the term of the lease. The Company recognizes rent expense on a straight-line basis over the lease term and accrues for rent expense incurred but not paid. As of December 31, 2021, future minimum operating lease commitments were as follows (in thousands) : Year Ending March 31, 2022 $ 177 2023 697 2024 666 Thereafter 156 Total $ 1,696 The Company recorded rent expense, net of rental income, which includes common area maintenance fees in addition to the base rent, of $196 thousand and $237 thousand for the three months ended December 31, 2021 and 2020, respectively, and of $661 thousand and $659 thousand for the nine months ended December 31, 2021 and 2020, respectively. Rental income from a noncancelable sublease was $0 and $45 thousand for the three months ended December 31, 2021 and 2020, respectively, and $0 and $136 thousand for the nine months ended December 31, 2021 and 2020, respectively. As of December 31, 2021, there are no future minimum rental payments to be received under the noncancelable sublease. Contingencies During the ordinary course of business, the Company may become a party to legal proceedings incidental to its business. The Company accrues contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. Legal cost is expensed as incurred. The Company is not aware of any material legal claims or assessments. Although the results of litigation and claims are inherently unpredictable, management believes there was not at least a reasonable possibility that the Company had incurred a material loss with respect to any loss contingencies as of December 31, 2021 and through the issuance of these financial statements. Indemnification The Company from time to time enters into types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily relate to: (1) real estate leases, under which the Company may be required to indemnify property owners for environmental and other liabilities and for other claims arising from the Company’s use of the applicable premises; (2) agreements with the Company’s officers, directors, and employees, under which the Company may be required to indemnify such persons from liabilities arising out of their relationship; (3) indemnifying customers in the event of product failure; and (4) agreements with outside parties that use the Company’s intellectual property, under which the Company may indemnify for copyright or patent infringement related specifically to the use of such intellectual property. Historically, the Company has not been required to make payments under these obligations, and no liabilities have been recorded for these obligations in the Company’s unaudited condensed consolidated financial statements. |
Stockholders' Equity (Deficit)
Stockholders' Equity (Deficit) | 9 Months Ended |
Dec. 31, 2021 | |
Equity [Abstract] | |
Stockholders' Equity (Deficit) | Stockholders’ Equity (Deficit) On February 12, 2020, in connection with the Merger, shares of Transphorm Technology’s convertible preferred stock and common stock issued and outstanding immediately prior to the closing of the Merger were converted into shares of the Company’s common stock as follows: • Series 1 convertible preferred stock: 51,680,254 shares issued and outstanding were converted into 12,433,953 shares issued and outstanding; • Series 2 convertible preferred stock: 38,760,190 shares issued and outstanding were converted into 7,499,996 shares issued and outstanding; • Series 3 convertible preferred stock: 31,850,304 issued and outstanding were converted into 4,000,000 shares issued and outstanding; and • Common stock: 50,325,662 shares issued and outstanding were converted into 4,171,571 shares, net of 52,733 redeemed shares from unaccredited investors, issued and outstanding. In addition, on February 12, 2020, the Company issued 1,650,000 shares in connection with the Merger with Peninsula Acquisition Corporation. All per share and share amounts for all periods presented have been retroactively adjusted to reflect the effect of the Merger. In December 2019, the Company amended its certificate of incorporation to authorize two classes of stock, to be designated, respectively, common stock and preferred stock. The total number of shares of stock that the Company has the authority to issue is 755,000,000 shares, of which 750,000,000 shares are common stock, $0.0001 par value per share, and 5,000,000 shares are preferred stock, $0.0001 par value per share. In April 2021, the Company issued 97,099 shares of common stock as payment of $500 thousand for one year internet advertising contract with SRAX, Inc. In October 2021, the Company issued 3,120,000 shares of common stock to Yaskawa upon the conversion of $15.6 million outstanding principal and accrued interest under the Yaskawa Note. As of December 31, 2021, 750,000,000 shares of common stock are authorized, of which 53,066,922 shares of common stock were issued and outstanding, and 5,000,000 shares of preferred stock are authorized, none of which were issued and outstanding. The Company’s Board of Directors has the ability to designate the rights, preferences and privileges for the preferred stock. Private Placements On February 12, 2020 and February 27, 2020, the Company sold an aggregate of 5,380,000 shares of common stock in a private placement offering at a purchase price of $4.00 per share, with aggregate gross proceeds of $21.5 million (before deducting placement agent fees and other offering expenses, which were an aggregate of $1.8 million). On December 23, 2020, the Company sold an aggregate of 5,000,000 shares of common stock in a private placement offering at a purchase price of $3.00 per share and issued warrants to placement agents to purchase 150,000 shares of common stock at a price of $3.30 per share, with aggregate gross proceeds of $15.0 million (before deducting placement agent fees, financial advisor fees and other offering expenses, which were an aggregate of $1.4 million excluding warrant cost of $223 thousand). On March 31, 2021, the Company sold 250,000 shares of common stock in a private placement offering at a purchase price of $4.00 per share, with gross proceeds of $1.0 million (before deducting placement agent fees and other offering expenses, which were an aggregate of $50 thousand). On August 13, 2021, the Company sold 1,000,000 shares of common stock in a private placement offering at a purchase price of $5.00 per share with gross proceeds of $5.0 million and issued warrants to purchase 209,000 shares of common stock at a price of $6.00 per share (before deducting legal cost of $22 thousand). On November 5, 2021 and November 9, 2021, the Company sold an aggregate of 6,600,000 shares of common stock in a private placement offering at a purchase price of $5.00 per share, with aggregate gross proceeds of $33.0 million (before deducting placement agent fees and other offering expenses, which were an aggregate of $840 thousand). Pursuant to the purchase agreements entered into with the investors in this offering, during the Second Investment Period (as described below), each investor has the right (but not the obligation), subject to the satisfaction of customary closing conditions, to purchase and acquire from the Company (i) additional shares of common stock at a purchase price of $5.00 per share (the “Second Closing Shares”) and (ii) additional warrants to purchase shares of common stock (the “Second Closing Warrants”). If this purchase option is exercised in full, the maximum number of Second Closing Shares and Second Closing Warrants that may be issued by the Company is 3,299,999 shares of common stock and warrants to purchase 687,501 shares of common stock. The “Second Investment Period” begins on the date of the applicable purchase agreement and ends on the earliest to occur of: (i) the third anniversary of the applicable agreement; (ii) a Change in Control (as defined in the purchase agreements), provided that the Company has given the investor at least 10 days’ prior written notice of such Change in Control; (iii) the tenth day after disclosure to the investor of a Change in Control, but only if the Company has not given prior written notice of such Change in Control to the investor in accordance with clause (ii); or (iv) the 90th day following the date on which the Company’s common stock is first listed on Nasdaq. On December 7, 2021, the Company sold 1,673,152 shares of common stock in a private placement offering at a purchase price of $7.71 per share, with aggregate gross proceeds of $12.9 million (before deducting a finder’s fee and other offering expenses, which were an aggregate of $286 thousand). Common Stock Common stockholders are entitled to dividends, as and when declared by the Company’s Board of Directors, subject to the priority dividend rights of the holders of other classes of stock. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote. The Company has reserved shares of common stock for future issuance as of date presented as follows: December 31, 2021 Equity incentive plans 7,021,949 Common stock warrants 2,742,065 Total 9,764,014 Common Stock Warrants On December 23, 2020, we issued warrants to purchase 150,000 shares of common stock at an exercise price of $3.30 per share. On August 13, 2021, we issued warrants to purchase 209,000 shares of common stock at an exercise price of $6.00 per share. On October 4, 2021, we issued warrants to purchase 650,000 shares of common stock at an exercise price of $6.00 per share. On November 5, 2021, we issued warrants to purchase 958,334 shares of common stock at an exercise price of $6.00 per share. On November 9, 2021, we issued warrants to purchase 416,667 shares of common stock at an exercise price of $6.00 per share. On December 7, 2021, we issued warrants to purchase 348,649 shares of common stock at an exercise price of $9.25 per share. These warrants are exercisable by paying cash or by cashless exercise for unregistered shares of common stock. The exercise price of the warrants is subject to standard antidilutive provision adjustment in the case of stock dividends or other distributions on shares of common stock or any other equity or equity equivalent securities payable in shares of common stock, stock splits, stock combinations, reclassifications or similar events affecting our common stock, and also, subject to limitations, upon any distribution of assets, including cash, stock or other property to our stockholders. The exercise price of the warrants is not subject to “price-based” anti-dilution adjustment. We have determined that these warrants related to issuance of common stock are subject to equity treatment because warrant holders have no right to demand cash settlement and there are no unusual anti-dilution rights. The following warrants to purchase common stock were outstanding as of December 31, 2021: Number of Shares Exercise Price Expiration Date 6,046 $ 34.74 5 years after an initial public offering of the Company 3,369 $ 54.41 5 years after an initial public offering of the Company 150,000 $ 3.30 December 23, 2025 209,000 $ 6.00 August 13, 2024 650,000 $ 6.00 October 4, 2024 958,334 $ 6.00 November 5, 2024 416,667 $ 6.00 November 9, 2024 348,649 $ 9.25 December 7, 2024 2,742,065 On January 5, 2022, the Company issued 13,028 shares of common stock in connection with the cashless exercise of a warrant. On January 10, 2022, the Company issued 82,500 shares of common stock in connection with the exercise of a warrant at an exercise price of $3.30 per share. |
Stock-Based Compensation
Stock-Based Compensation | 9 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Stock-Based Compensation | Stock-Based Compensation The 2020 Equity Incentive Plan (the “2020 Plan”) was approved by Transphorm Technology’s board of directors on February 10, 2020 and Transphorm Technology’s stockholders on February 12, 2020, and became effective on the business day immediately prior to the closing of the Merger. Our stockholders approved the 2020 Plan on February 11, 2020. We assumed the 2020 Plan in connection with the Merger. The 2020 Plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”), to our employees and our parent and subsidiary corporations’ employees, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units (“RSUs”), performance units, and performance shares to our employees, directors, and consultants and our parent and subsidiary corporations’ employees and consultants. As of December 31, 2021, there were 1,248,007 restricted stock units outstanding under the 2020 Plan, 2,957,904 stock options outstanding under the 2020 Plan, and 2,816,038 shares available for grant (which includes an automatic increase of 2,026,599 shares on April 1, 2021) under the 2020 Plan. Subject to the adjustment provisions of the 2020 Plan, and the automatic increase described in the 2020 Plan, the maximum aggregate number of shares of our common stock that may be issued under the 2020 Plan is 5,050,000 shares of our common stock, which includes (i) 2,588,077 shares initially reserved for issuance, plus (ii) any shares of our common stock subject to issued and outstanding awards under the 2007 Plan or 2015 Plan that were assumed in the Merger and that, on or after the closing of the Merger, expire or otherwise terminate without having been exercised or issued in full, are tendered to or withheld by us for payment of an exercise price or for tax withholding obligations, or are forfeited to or repurchased by us due to failure to vest, with the maximum number of shares to be added to the 2020 Plan pursuant to this clause (ii) equal to 2,461,923 shares. Subject to the adjustment provisions of the 2020 Plan, the number of shares of common stock available for issuance under the 2020 Plan will also include an annual increase on the first day of each fiscal year beginning with our 2022 fiscal year and ending on (and including) our 2030 fiscal year, in an amount equal to the least of: 5,000,000 shares of our common stock; five Stock Options The following table summarizes stock option activity and related information for the periods presented: Number of Options Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (1) (in thousands) Outstanding at October 1, 2021 2,506,531 $ 4.77 5.67 $ 590 Options granted 473,077 $ 6.52 Options exercised — $ — Options canceled (21,704) $ 9.32 Outstanding at December 31, 2021 2,957,904 $ 5.02 6.14 $ 9,218 Exercisable at December 31, 2021 2,227,540 $ 4.61 5.00 $ 7,958 Outstanding at October 1, 2020 2,327,423 $ 4.68 6.16 $ 167 Options granted — $ — Options exercised — $ — Options canceled (7,105) $ 8.96 Outstanding at December 31, 2020 2,320,318 $ 4.67 5.92 $ — Exercisable at December 31, 2020 2,267,154 $ 4.70 5.86 $ — (1) Intrinsic value represents the excess of the fair value on the last day of the period, which was $8.00 and $3.00 as of December 31, 2021 and 2020, respectively, over the exercise price, multiplied by the number of options. Number of Options Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (1) (in thousands) Outstanding at April 1, 2021 2,543,125 $ 4.82 6.05 $ — Options granted 528,077 $ 6.31 Options exercised (31,925) $ 4.21 Options canceled (81,373) $ 7.46 Outstanding at December 31, 2021 2,957,904 $ 5.02 6.14 $ 9,218 Exercisable at December 31, 2021 2,227,540 $ 4.61 5.00 $ 7,958 Outstanding at April 1, 2020 2,458,091 $ 4.74 6.58 $ — Options granted — $ — Options exercised (3,475) $ 3.80 Options canceled (134,298) $ 6.01 Outstanding at December 31, 2020 2,320,318 $ 4.67 5.92 $ — Exercisable at December 31, 2020 2,267,154 $ 4.70 5.86 $ — (1) Intrinsic value represents the excess of the fair value on the last day of the period, which was $8.00 and $3.00 as of December 31, 2021 and 2020, respectively, over the exercise price, multiplied by the number of options. Stock-based compensation expense is determined based on the fair value of the Company’s common stock as determined by the Board of Directors and assumptions such as volatility, expected term, risk-free interest rates, and other factors. Changes in the deemed fair value of the common stock, the underlying assumptions in the calculations, the number of options granted or the terms of such options, the expected forfeiture rate, the treatment of tax benefits and other changes may result in significant differences in the amounts or timing of the compensation expense recognized. The assumptions and estimates are made as follows: • Expected Volatility - The Company utilizes the historical volatility of representative public companies to determine its expected volatility, as the trading history of the Company’s common stock is limited. • Estimated Forfeitures - The Company adopted ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting and has elected to account for forfeitures as they occur and therefore, stock-based compensation expense has been calculated based on actual forfeitures in the statements of operations, rather than our previous approach which was net of estimated forfeitures. The net cumulative effect of this change was not material. • Expected Dividend Yield - The Company has not issued any common stock dividends; therefore, a dividend yield of zero was used. • Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes-Merton option pricing model on the implied yield currently available on United States Treasury zero-coupon issues with an equivalent expected term. • Expected Term - The expected term of stock options represents the period that the Company’s stock options are expected to be outstanding. The Company generally uses the simplified method to calculate the expected term for employee grants. The assumptions used to value options granted to employees during the periods presented was as follows: Three Months Ended December 31, Nine Months Ended December 31, 2021 2020 2021 2020 Weighted average expected life (in years) 5.85 — 5.88 — Risk-free interest rate 1.32% — 1.30% — Expected volatility 42.65% — 42.77% — Grant date fair market value $6.55 — $6.34 — Grant date fair value $3.11 — $2.99 — Dividend yield —% — —% — Restricted Stock Restricted Stock Awards RSAs are grants of shares of our common stock that vest in accordance with terms and conditions established by the Company’s Board of Directors. Recipients of RSAs generally will have voting and dividend rights with respect to such shares upon grant without regard to vesting, unless the RSA agreement provides otherwise. Shares of restricted stock that do not vest are subject to forfeiture. In September 2020, we granted 123,501 RSAs outside of our 2020 Plan, 98,450 of which were fully vested on the date of grant and the remainder of which vested in January 2021. In December 2020, we granted 12,000 RSAs outside of our 2020 Plan, all of which were fully vested on the date of grant. There were no RSAs outstanding as of March 31, 2021 and no RSA activities during the three and nine months ended December 31, 2021. Restricted Stock Units RSUs are grants of shares of our common stock that vest in accordance with terms and conditions established by the administrator of the 2020 Plan. Subject to the provisions of the 2020 Plan, the administrator determines the terms and conditions of RSUs, including the vesting criteria. We granted 816,180 RSUs during the three months ended September 30, 2020, 4,000 of which were fully vested on the date of grant. The remainder of the RSUs are scheduled to vest as follows: one third will vest on each of January 1, 2022, January 1, 2023 and July 1, 2023, in each case subject to the RSU holders’ continued status as a service provider to the Company through each vesting date. We granted 137,452 RSUs during the three months ended March 31, 2021, which are scheduled to vest in various periods, beginning immediately and ending on February 2025, in each case subject to the RSU holders’ continued status as a service provider to the Company through each vesting date. We granted 35,000 RSUs during the three months ended September 30, 2021, 25 percent of which are scheduled to vest after one year and the remainder are scheduled to vest each quarter for three years, in each case subject to the RSU holders’ continued status as a service provider to the Company through each vesting date. We granted 307,640 RSUs during the three months ended December 31, 2021, 25% of which are scheduled to vest annually over four years on each anniversary of the vesting commencement date, in each case subject to the RSU holders’ continued status as a service provider to the Company through the applicable vesting date. The following table summarizes RSU activity and related information for the periods presented: December 31, 2021 Three Months Ended Nine Months Ended Number of Shares Weighted-Average Grant Date Fair Value Per Share Number of Shares Weighted-Average Grant Date Fair Value Per Share Balance at beginning of period 951,637 $ 3.96 935,397 $ 3.96 Granted 307,640 $ 6.60 342,640 $ 6.31 Vested (9,750) $ 3.75 (12,750) $ 3.75 Canceled (1,520) $ 3.85 (17,280) $ 3.97 Balance at end of period 1,248,007 $ 4.61 1,248,007 $ 4.61 December 31, 2020 Three Months Ended Nine Months Ended Number of Shares Weighted-Average Grant Date Fair Value Per Share Number of Shares Weighted-Average Grant Date Fair Value Per Share Balance at beginning of period 812,180 $ 4.00 — $ — Granted — $ — 816,180 $ 4.00 Vested — $ — (4,000) $ 4.00 Canceled (6,855) $ 4.00 (6,855) $ 4.00 Balance at end of period 805,325 $ 4.00 805,325 $ 4.00 Stock-Based Compensation The accompanying unaudited condensed consolidated statement of operations and comprehensive loss includes stock-based compensation expense for the periods presented as follows (in thousands) : Three Months Ended December 31, Nine Months Ended December 31, 2021 2020 2021 2020 Cost of revenue $ 52 $ 50 $ 118 $ 78 Research and development 145 158 383 260 Sales and marketing 88 45 159 61 General and administrative 563 452 1,196 994 Total $ 848 $ 705 $ 1,856 $ 1,393 Unrecognized Stock-Based Compensation Unrecognized stock-based compensation expense as of dates presented was as follows (in thousands) : December 31, 2021 December 31, 2020 Unrecognized Expense Average Expected Recognition Period (in years) Unrecognized Expense Average Expected Recognition Period (in years) Stock options $ 1,531 2.23 $ 54 0.67 Restricted stock 3,117 1.74 2,687 1.87 Total $ 4,648 1.90 $ 2,741 1.85 |
Related Party Transactions
Related Party Transactions | 9 Months Ended |
Dec. 31, 2021 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Related Party Transactions During the three months ended December 31, 2021, the Company entered into the following related party transactions: • Recorded $791 thousand in cost of goods sold for services, recorded $102 thousand in research and development expense, purchased $70 thousand of inventory, paid $55 thousand in consumption tax and incurred $124 thousand for employees and related benefits from the AFSW joint venture; • Recorded $375 thousand in revenue per a cooperation and development agreement with Yaskawa and $1.2 million gain in other income on Yaskawa promissory note conversion; • Recorded $251 thousand in revenue from GaNovation; and • Recorded $38 thousand of reimbursements in license maintenance fee, recorded $184 thousand in interest expense, and sold $504 thousand of products to Nexperia. See Note 2 - Nexperia Arrangement. During the nine months ended December 31, 2021, the Company entered into the following related party transactions: • Recorded $1.5 million as gain in other income, recorded $2.3 million in cost of goods sold for services, recorded $401 thousand in research and development expense, purchased $140 thousand of inventory, paid $92 thousand in consumption tax and incurred $221 thousand for employees and related benefits from the AFSW joint venture; • Sold $19 thousand of products to non-controlling stockholders of the Company, incurred $111 thousand of license maintenance fee and recorded $176 thousand in consulting expense from a non-controlling stockholder of the Company; • Recorded $1.1 million in revenue per a cooperation and development agreement with Yaskawa and $1.2 million gain in other income on Yaskawa promissory note conversion; • Recorded $405 thousand in revenue from GaNovation; and • Recorded $8.5 million in license fee income, recorded $113 thousand of reimbursements in license maintenance fee, recorded $534 thousand in interest expense, and sold $1.0 million of products to Nexperia. See Note 2 - Nexperia Arrangement. As of December 31, 2021, total due from related parties was $1.8 million, consisting of $1.3 million due from the AFSW joint venture, $186 thousand accounts receivable from GaNovation, and $374 thousand accounts receivable from a stockholder and noteholder of the Company. As of December 31, 2021, total accounts payable to related parties was $684 thousand to the AFSW joint venture and $74 thousand to Nexperia. During the three months ended December 31, 2020, the Company entered into the following related party transactions: • Recorded $13 thousand in cost of goods sold for services and recorded $152 thousand reimbursement of research and development and recorded negative $11 thousand in payroll related cost from the AFSW joint venture; • Sold $12 thousand of products to non-controlling stockholders of the Company and incurred $50 thousand of license maintenance fee from a non-controlling stockholder of the Company; and • Recorded $21 thousand in license fee income, recorded $421 thousand in EPI Gen 4 Wafer growth sales, recorded $38 thousand of reimbursements in license maintenance fee, recorded $153 thousand in interest expense and sold $38 thousand of products to Nexperia. See Note 2 - Nexperia Arrangement. During the nine months ended December 31, 2020, the Company entered into the following related party transactions: • Recorded $130 thousand in cost of goods sold for services, recorded research and development expense of $674 thousand and recorded $14 thousand in payroll related costs from the AFSW joint venture; • Sold $152 thousand of products to non-controlling stockholders of the Company and incurred $150 thousand of license maintenance fee from a non-controlling stockholder of the Company; and • Recorded $5.2 million in license fee income, recorded $701 thousand EPI Gen 4 Wafer growth sales, recorded $113 thousand of reimbursements in license maintenance fee, recorded $458 thousand in interest expense, recorded $231 thousand reimbursement for research and development, and sold $571 thousand of products to Nexperia. See Note 2 - Nexperia Arrangement. As of March 31, 2021, total due from related parties was $14.1 million, consisting of $13.5 million due from the AFSW joint venture, $5 thousand accounts receivable from non-controlling stockholders of the Company, and $503 thousand accounts receivable from Nexperia. As of March 31, 2021, total accounts payable to related parties was $370 thousand to the AFSW joint venture and $11 thousand to Nexperia, and accrued royalty was $4 thousand to Furukawa. |
Subsequent Events
Subsequent Events | 9 Months Ended |
Dec. 31, 2021 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent EventsThe Company has evaluated subsequent events through the issuance of these financial statements and is not aware of any material items that would require disclosure in the notes to the financial statements or would be required to be recognized as of December 31, 2021. |
Business and Basis of Present_2
Business and Basis of Presentation (Policies) | 9 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Principles of Consolidation | The unaudited condensed consolidated financial statements include the accounts of the Parent and its wholly-owned subsidiaries, Transphorm Technology, Transphorm Japan, Inc., Transphorm Japan Epi, Inc. and Transphorm Aizu, Inc. Upon consolidation, all significant intercompany accounts and transactions have been eliminated. |
Use of Estimates | The preparation of interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management bases its estimates and assumptions on historical experience, knowledge of current conditions, and its belief of what could occur in the future, given available information. Actual results could differ from those estimates, and such differences could be material to the consolidated financial statements. Estimates are used for, but not limited to, the determinations of fair value of stock awards and promissory notes, accrual of liabilities, revenue recognition, inventory reserve, and useful lives for property and equipment. |
Cash, Cash Equivalents and Restricted Cash | The Company considers all highly-liquid investments with original maturities of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents consist principally of bank deposits and money market funds. |
Foreign Currency Risk | The Company is exposed to foreign currency risk due to its operations in Japan (Yen). Assets and liabilities of the operations are re-measured into U.S. currency at exchange rates in effect at the balance sheet dates through the consolidated statements of comprehensive income. Gains or losses resulting from foreign currency transactions are re-measured using the rates on the dates on which those elements are recognized during the period and are included in other income or expense in the consolidated statements of operations. |
Concentrations of Risk | Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company is exposed to credit risk in the event of default by the financial institution holding its cash. The Company’s investment policy restricts investments to high-quality investments and limits the amounts invested with any one issuer, industry or geographic area. Risks associated with cash holdings in excess of insured limits are mitigated by banking with high-quality institutions. To date, the Company has not experienced any significant losses on its cash and cash equivalents. The Company periodically evaluates the relative credit standing of these financial institutions. The Company is subject to risks common in the power conversion components industry, including, but not limited to, technological obsolescence, dependence on key personnel, market acceptance of its products, the successful protection of its proprietary technologies, compliance with government regulations, and the possibility of not being able to obtain additional financing when needed. |
Comprehensive Loss | Comprehensive loss is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) includes the impact of foreign currency translation adjustments. |
Accounts Receivable | Accounts receivable are analyzed and allowances for uncollectible accounts are recorded, as required. Provisions for uncollectible accounts, if any, are recorded as bad debt expense and included in general and administrative expenses in the accompanying consolidated statements of operations. The process for determining the appropriate level of allowances for doubtful accounts involves judgment, and the Company considers such factors as the age of the underlying receivables, historical and projected collection trends, the composition of outstanding receivables, current economic conditions and regulatory changes. An account is fully reserved when reasonable collection efforts have been unsuccessful and it is probable that the receivable will not be recovered. |
Inventory | Inventory is stated at the lower of cost (first-in, first-out method) or net realizable value. The Company periodically reviews the value of items in inventory and records write-downs or write-offs based on its assessment of slow moving or obsolete inventory. The Company maintains an inventory reserve for obsolete inventory and generally makes inventory value adjustments against the inventory reserve. |
Property and Equipment | Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is determined using the straight-line method over the estimated useful lives of the respective assets, generally ranging from three |
Property and Equipment, Impairment | The Company evaluates the carrying amount of its property and equipment whenever events or changes in circumstances indicate that the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of an asset or asset group and its eventual disposition are less than the carrying amount of the asset or asset group. |
Goodwill | Goodwill arose for the acquisition of a business in February 2014 based in Japan and was accounted for as the purchase of a business. Goodwill generated from business combinations and deemed to have indefinite lives are not subject to amortization and instead are tested for impairment at least annually in December unless certain events occur or circumstances change. Goodwill represents the excess of the purchase price over the fair value of the net assets and other identifiable intangible assets acquired. We test for goodwill impairment annually, March 31, or earlier if events or changes in circumstances indicate goodwill might possibly be impaired. Impairment exists when the carrying value of the goodwill exceeds its implied fair value. An impairment loss would be recognized in an amount equal to that excess as a charge to operations in the unaudited condensed consolidated statements of operations. |
Intangible Assets | Intangible assets that are not considered to have an indefinite useful life are amortized over their estimated useful lives, which generally range from three |
Revenue Recognition | The Company derives its revenues from sales of high-powered GaN-based products manufactured utilizing the Company’s proprietary and patented epiwafer technology and wafer fabrication and other assembly processes, sales of GaN epiwafers for the radio frequency (“RF”) and power markets, and sales of licenses to use such patented proprietary technology, as well as enabling EPI wafer growth services and products to our strategic partners. Revenues are recognized when control of these products or licenses are transferred to the Company’s customers in an amount that reflects the consideration it expects to be entitled to in exchange for those products and licenses. Sales and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. Incidental items that are immaterial in the context of the contract are recognized as expense. The Company does not have any significant financing components associated with its revenue contracts, as payment is received at or shortly after the point of sale. Disaggregation of Revenue from Contracts with Customers Revenue consists of licensing revenue, government contract revenue from our contract with the U.S. Navy and product sales, with applicable performance obligations satisfied at a point in time. Products are sold to distributors and end-users in various sectors such as, but not limited to, the automotive, gaming, industrial, IT, and consumer products industries. As part of the multi-element commercial arrangement executed with Nexperia on April 4, 2018 (see Note 2 - Nexperia Arrangement), the Company agreed to grant Nexperia the perpetual exclusive right to use the Company’s existing Gen-3 manufacturing process technology. License fees are received upon satisfaction of contractual milestones and recognized upon delivery of the perpetual license or transferred technology without any remaining performance obligations. The Company recognized $0 and $8.0 million of licensing revenue for the three and nine months ended December 31, 2021, respectively, and $0 and $5.0 million of licensing revenue for the three and nine months ended December 31, 2020, respectively. In December 2020, the Company entered into a cooperation and development agreement with Yaskawa Electric Corporation (“Yaskawa”), pursuant to which Yaskawa agreed to provide $4.0 million over approximately three years to fund development activities related to industrial power conversion applications, with an initial focus on servo motor drive applications. Yaskawa provided payments of $1.0 million and $750 thousand of this $4.0 million commitment in December 2020 and July 2021, respectively. The Company evaluated and concluded that the deliverables are the same and nature of the services to be provided to Yaskawa will be consistent over the period of approximately three years. Accordingly, the Company recognized $333 thousand as revenue in each of the three months ended December 31, 2020, March 31, 2021 and June 30, 2021 and recognized $375 thousand as revenue in each of the three months ended September 30, 2021 and December 31, 2021. Government contract revenues are principally generated under research and development contracts. Contract revenues are derived primarily from research contracts with agencies of the U.S. government. We believe credit risk related to accounts receivable arising from such contracts is minimal. These contracts may include cost-plus fixed fee and fixed price terms. All payments to us for work performed on contracts with agencies of the U.S. government are subject to adjustment upon audit by the Defense Contract Audit Agency. The contract expires March and June 2022 and the Company is working on an extension. The Company received new government authorized rates for billing purposes which allowed for retroactive application since inception. The cumulative impact of this rate change as of December 31, 2021 was $423 thousand, of which $(83) thousand and $505 thousand were recorded in the three months ended March 31, 2021 and September 30, 2020, respectively. The Company will use the new approved rates on a go-forward basis. Performance Obligations For performance obligations related to the sale of products, control transfers to the customer at a point in time. The Company’s principal terms of sale are free on board shipping or destination and the Company transfers control and records revenue for product sales upon shipment or delivery to the customer, respectively. For performance obligations related to the licensing of patented technology in perpetuity, control also transfers to the customer at a point in time. The Company transfers control and records revenue for licensing fees once the Company has (i) provided or otherwise makes available the patented technology to the customer and (ii) the customer is able to use and benefit from the patented technology. Variable Consideration The nature of the Company’s arrangement with Nexperia gives rise to variable consideration in the form of milestone and royalty payments. The royalties qualify for the sales and usage-based royalty exception, as the license of intellectual property is the predominant item to which the royalty relates and are recognized upon the subsequent sale occurring. The variable amounts are received upon satisfaction of contractually agreed upon development targets and sales volume. |
Research and Development | The Company is a party to research grant contracts with the U.S. government for which the Company is reimbursed for specified costs incurred for its research projects. These projects include energy saving initiatives for which the U.S. government offers reimbursement funds. Such reimbursements are recorded as an offset to research and development expenses when the related qualified research and development expenses are incurred. Reimbursable costs are recognized in the same period the costs are incurred up to the limit of approved funding amounts on qualified expenses. |
Stock-based compensation expense | All share-based payments, including grants of stock options, restricted stock awards (“RSAs”) and restricted stock units (“RSUs”), are measured at the fair value of the share-based awards on the grant date and recognized over their respective vesting periods, which is generally one RSUs are measured using the fair market value of the stock price at grant date. The Company recognizes the fair value of share-based payments as compensation expense for all expected-to-vest stock-based awards over the vesting period of the award using the straight-line attribution or graded vesting method provided that the amount of compensation cost recognized at any date is no less than the portion of the grant-date fair value of the award that is vested at that date. The Black-Scholes-Merton option pricing model requires inputs such as the fair value of common stock on date of grant, expected term, expected volatility, dividend yield, and risk-free interest rate. Further, the forfeiture rate also affects the amount of aggregate compensation expense. These inputs are subjective and generally require significant analysis and judgment to develop. Volatility data is obtained from a study of publicly traded industry peer companies. The forfeiture rate is derived primarily from the Company’s historical data, and the risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues commensurate with the expected term. Management generally uses the simplified method to calculate the expected term for employee grants as the Company has limited historical exercise data or alternative information to reasonably estimate an expected term assumption. The simplified method assumes that all options will be exercised midway between the weighted average vesting date and the contractual term of the option. Stock-based compensation expense recognized in the Company’s unaudited condensed consolidated financial statements is based on awards that are expected to vest. These expense amounts have been reduced by using an estimated forfeiture rate. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company evaluates the assumptions used to estimate forfeitures annually in connection with the recognition of stock-based compensation expense. Stock-based compensation expense is determined based on the fair value of the Company’s common stock as determined by the Board of Directors and assumptions such as volatility, expected term, risk-free interest rates, and other factors. Changes in the deemed fair value of the common stock, the underlying assumptions in the calculations, the number of options granted or the terms of such options, the expected forfeiture rate, the treatment of tax benefits and other changes may result in significant differences in the amounts or timing of the compensation expense recognized. The assumptions and estimates are made as follows: • Expected Volatility - The Company utilizes the historical volatility of representative public companies to determine its expected volatility, as the trading history of the Company’s common stock is limited. • Estimated Forfeitures - The Company adopted ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting and has elected to account for forfeitures as they occur and therefore, stock-based compensation expense has been calculated based on actual forfeitures in the statements of operations, rather than our previous approach which was net of estimated forfeitures. The net cumulative effect of this change was not material. • Expected Dividend Yield - The Company has not issued any common stock dividends; therefore, a dividend yield of zero was used. • Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes-Merton option pricing model on the implied yield currently available on United States Treasury zero-coupon issues with an equivalent expected term. • Expected Term - The expected term of stock options represents the period that the Company’s stock options are expected to be outstanding. The Company generally uses the simplified method to calculate the expected term for employee grants. |
Income (Loss) Per Share | Basic income (loss) per share is calculated by dividing net income (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is calculated by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares outstanding plus potential dilutive common shares outstanding during the period. Potential dilutive securities, comprised of stock warrants, restricted stock units and stock options, are not reflected in diluted income (loss) per share because such shares are anti–dilutive. Dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. |
Fair Value Measurement | Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying values of the Company’s financial instruments such as cash equivalents, accounts receivable, revolving credit facility, accounts payable and accrued liabilities approximate fair values due to the short-term nature of these items. |
Income Taxes | The Company accounts for income taxes in accordance with Accounting Standards Codification (“ASC”) 740, Income Taxes (“ASC 740”). ASC 740 prescribes the use of the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and the tax basis of assets and liabilities and are measured using the enacted statutory tax rates in effect at the balance sheet date. The |
Equity Method Investments | The Company uses the equity method to account for investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. The Company's proportionate share of the net income or loss of these companies is included in consolidated net loss. Judgments regarding the level of influence over each equity method investment include consideration of key factors such as the Company's ownership interest, representation on the board of directors or other management body and participation in policy-making decisions. |
Segment Reporting | The Company’s operations and its financial performance is evaluated on a consolidated basis by the chief operating decision maker. The Company’s chief operating decision maker is the Parent’s Chief Executive Officer. Accordingly, the Company considers all of its operations to be aggregated in one reportable operating segment. |
Recently Issued Accounting Standards under Evaluation | Recently Issued Accounting Standards under Evaluation Debt - In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to address the complexity in accounting for certain financial instruments with characteristics of liabilities and equity. Amongst other provisions, the amendments in this ASU significantly change the guidance on the issuer’s accounting for convertible instruments and the guidance on the derivative scope exception for contracts in an entity’s own equity such that fewer conversion features will require separate recognition, and fewer freestanding instruments, like warrants, will require liability treatment. Refer to our white paper, Accounting simplifications for convertible instruments and warrants, for additional information. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact of this new standard on its consolidated financial statements and the adoption is not expected to have a significant impact on the consolidated financial statements. Leases - In June 2020, the FASB issued ASU 2020-05, which amends the effective dates of the FASB’s standards on leasing (ASC 842) to give immediate relief to certain entities as a result of the widespread adverse economic effects and business disruptions caused by the COVID-19 pandemic. In February 2016, the FASB issued ASU 2016-02, Leases , which, for operating leases, requires the lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, on its balance sheet. The guidance also requires a lessee to recognize single lease costs, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. The leasing standard’s effective dates were the fiscal year beginning after December 15, 2019 as originally issued (ASU 2016-02) and the fiscal year beginning after December 15, 2020 as amended by ASU 2019-10. As amended by ASU 2020-05, the leasing standard’s effective date is now the fiscal year beginning after December 15, 2021. The Company is currently evaluating the impact of this new standard on its consolidated financial statements and the adoption is not expected to have a significant impact on the consolidated financial statements. Financial Instruments - FASB ASU 2020-03, Codification Improvements to Financial Instruments , makes clear the determination of the contractual life of a net investment in leases in estimating expected credit losses under ASC 326, Financial Instruments – Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The standard changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. ASU 2016-13 is effective for the Company in 2023. Early adoption is permitted. The Company is currently evaluating the impact of this new standard on its consolidated financial statements and the adoption is not expected to have a significant impact on the consolidated financial statements. Income Tax - In December 2019, the FASB issued ASU 2019-12, which modifies ASC 740 to simplify the accounting for income taxes. The ASU’s amendments are based on changes that were suggested by stakeholders as part of the FASB’s simplification initiative (i.e., the FASB’s effort to reduce the complexity of accounting standards while maintaining or enhancing the helpfulness of information provided to financial statement users). ASU 2019-12 is effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact of this new standard on its consolidated financial statements and the adoption is not expected to have a significant impact on the consolidated financial statements. |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 9 Months Ended |
Dec. 31, 2021 | |
Fair Value Disclosures [Abstract] | |
Liabilities measured at fair value by level | The following table summarizes the Company’s liabilities measured at fair value as of the dates presented, by level within the fair value hierarchy (in thousands) : Level 1 Level 2 Level 3 December 31, 2021 Promissory note $ — $ — $ — March 31, 2021 Promissory note $ — $ — $ 16,128 |
Changes in fair value of promissory notes | The following table includes the changes in fair value of the promissory note which are Level 3 on the fair value hierarchy (in thousands) : April 1, 2021 $ 16,128 Interest expense accrued 77 Increase in fair value (605) Conversion (15,600) December 31, 2021 $ — April 1, 2020 $ 13,885 Interest expense accrued 150 Increase in fair value 2,093 March 31, 2021 $ 16,128 |
Fair value of promissory note | The following table summarizes assumptions used for fair value of promissory note as of the dates presented: December 31, 2021 March 31, 2021 Stock price — $3.75 Time — 1.5 years Risk-free rate — 0.12% Volatility — 50.6% |
Concentration of Credit Risk _2
Concentration of Credit Risk and Significant Customers (Tables) | 9 Months Ended |
Dec. 31, 2021 | |
Risks and Uncertainties [Abstract] | |
Schedules of concentration of risk, by risk factor | Significant customers are those that represent 10% or more of revenue or accounts receivable and are set forth in the following table: Accounts Receivable As of December 31, 2021 March 31, 2021 Customer A 15.3% 31.1% Customer B 21.1% 33.9% Customer C 39.7% * Customer D * 10.0% Revenue for the Three Months Ended December 31, Revenue for the Nine Months Ended December 31, 2021 2020 2021 2020 Customer A 10.9% 23.8% 49.8% 62.6% Customer B 21.3% 43.9% 15.7% 26.6% Customer C 41.2% * 16.1% * Customer D * * * * * Less than 10% of total |
Inventory (Tables)
Inventory (Tables) | 9 Months Ended |
Dec. 31, 2021 | |
Inventory Disclosure [Abstract] | |
Schedule of inventory | Inventory consists of the following as of the dates presented (in thousands) : December 31, 2021 March 31, 2021 Raw materials $ 2,423 $ 626 Work in process 2,191 1,054 Finished goods 1,342 543 Total $ 5,956 $ 2,223 |
Debts (Tables)
Debts (Tables) | 9 Months Ended |
Dec. 31, 2021 | |
Debt Disclosure [Abstract] | |
Schedule of promissory note obligation | The Company’s stated value of promissory note obligation as of the dates presented consists of the following (in thousands) : Interest Rate Due Date December 31, 2021 March 31, 2021 Yaskawa Note 1.00% September 2022 $ — $ 15,523 |
Schedule of fair value option | As of the dates presented, the Company determined the fair value for the note, as compared to the face value, including accrued interest, as follows (in thousands) : December 31, 2021 March 31, 2021 Yaskawa Note $ — $ 16,128 |
Schedule of maturities of long-term debt | As of December 31, 2021, the scheduled maturity, including accrued interest, of the Company’s borrowings under the Tranche C Loans was as follows (in thousands) : Year Ending March 31, 2022 $ 368 2023 — 2024 12,000 Total $ 12,368 |
Investment in Aizu Fujitsu Se_2
Investment in Aizu Fujitsu Semiconductor Wafer Solution Limited ("AFSW") (Tables) | 9 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Schedule of investment activities in AFSW | The Company’s investment activities in AFSW for the periods presented are summarized below (in thousands) : For the Nine Months Ended December 31, 2021 For the Year Ended March 31, 2021 Beginning balance $ (1,866) $ (1,546) Investment 3,765 6,768 Loss (3,294) (6,885) Gain 1,455 — Effect of exchange rate change 1 (203) Ending balance $ 61 $ (1,866) (in thousands) : As of December 31, 2021 March 31, 2021 Current assets $ 1,844 $ 932 Long-term assets $ 5,152 $ 5,330 Other current liabilities $ 3,494 $ 2,200 Due to controlling owner $ 3,707 $ 22,354 Due to Transphorm $ 594 $ 13,179 Net deficit $ (799) $ (31,471) For the Three Months Ended December 31, For the Nine Months Ended December 31, 2021 2020 2021 2020 Sales $ 2,262 $ 698 $ 5,957 $ 1,728 Gross loss $ (2,338) $ (2,896) $ (7,094) $ (9,214) Net loss $ (2,848) $ (3,303) $ (9,085) $ (11,057) |
Commitment and Contingencies (T
Commitment and Contingencies (Tables) | 9 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of future minimum operating lease commitments | As of December 31, 2021, future minimum operating lease commitments were as follows (in thousands) : Year Ending March 31, 2022 $ 177 2023 697 2024 666 Thereafter 156 Total $ 1,696 |
Stockholders' Equity (Deficit)
Stockholders' Equity (Deficit) (Tables) | 9 Months Ended |
Dec. 31, 2021 | |
Equity [Abstract] | |
Schedule of convertible preferred stock by class | The Company has reserved shares of common stock for future issuance as of date presented as follows: December 31, 2021 Equity incentive plans 7,021,949 Common stock warrants 2,742,065 Total 9,764,014 |
Schedule of stockholders' equity note, warrants or rights | The following warrants to purchase common stock were outstanding as of December 31, 2021: Number of Shares Exercise Price Expiration Date 6,046 $ 34.74 5 years after an initial public offering of the Company 3,369 $ 54.41 5 years after an initial public offering of the Company 150,000 $ 3.30 December 23, 2025 209,000 $ 6.00 August 13, 2024 650,000 $ 6.00 October 4, 2024 958,334 $ 6.00 November 5, 2024 416,667 $ 6.00 November 9, 2024 348,649 $ 9.25 December 7, 2024 2,742,065 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 9 Months Ended |
Dec. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of stock option activity | The following table summarizes stock option activity and related information for the periods presented: Number of Options Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (1) (in thousands) Outstanding at October 1, 2021 2,506,531 $ 4.77 5.67 $ 590 Options granted 473,077 $ 6.52 Options exercised — $ — Options canceled (21,704) $ 9.32 Outstanding at December 31, 2021 2,957,904 $ 5.02 6.14 $ 9,218 Exercisable at December 31, 2021 2,227,540 $ 4.61 5.00 $ 7,958 Outstanding at October 1, 2020 2,327,423 $ 4.68 6.16 $ 167 Options granted — $ — Options exercised — $ — Options canceled (7,105) $ 8.96 Outstanding at December 31, 2020 2,320,318 $ 4.67 5.92 $ — Exercisable at December 31, 2020 2,267,154 $ 4.70 5.86 $ — (1) Intrinsic value represents the excess of the fair value on the last day of the period, which was $8.00 and $3.00 as of December 31, 2021 and 2020, respectively, over the exercise price, multiplied by the number of options. Number of Options Weighted Average Exercise Price per Share Weighted Average Remaining Contractual Term (in years) Aggregate Intrinsic Value (1) (in thousands) Outstanding at April 1, 2021 2,543,125 $ 4.82 6.05 $ — Options granted 528,077 $ 6.31 Options exercised (31,925) $ 4.21 Options canceled (81,373) $ 7.46 Outstanding at December 31, 2021 2,957,904 $ 5.02 6.14 $ 9,218 Exercisable at December 31, 2021 2,227,540 $ 4.61 5.00 $ 7,958 Outstanding at April 1, 2020 2,458,091 $ 4.74 6.58 $ — Options granted — $ — Options exercised (3,475) $ 3.80 Options canceled (134,298) $ 6.01 Outstanding at December 31, 2020 2,320,318 $ 4.67 5.92 $ — Exercisable at December 31, 2020 2,267,154 $ 4.70 5.86 $ — (1) Intrinsic value represents the excess of the fair value on the last day of the period, which was $8.00 and $3.00 as of December 31, 2021 and 2020, respectively, over the exercise price, multiplied by the number of options. |
Schedule of valuation assumptions | The assumptions used to value options granted to employees during the periods presented was as follows: Three Months Ended December 31, Nine Months Ended December 31, 2021 2020 2021 2020 Weighted average expected life (in years) 5.85 — 5.88 — Risk-free interest rate 1.32% — 1.30% — Expected volatility 42.65% — 42.77% — Grant date fair market value $6.55 — $6.34 — Grant date fair value $3.11 — $2.99 — Dividend yield —% — —% — |
Schedule of unvested restricted stock units | The following table summarizes RSU activity and related information for the periods presented: December 31, 2021 Three Months Ended Nine Months Ended Number of Shares Weighted-Average Grant Date Fair Value Per Share Number of Shares Weighted-Average Grant Date Fair Value Per Share Balance at beginning of period 951,637 $ 3.96 935,397 $ 3.96 Granted 307,640 $ 6.60 342,640 $ 6.31 Vested (9,750) $ 3.75 (12,750) $ 3.75 Canceled (1,520) $ 3.85 (17,280) $ 3.97 Balance at end of period 1,248,007 $ 4.61 1,248,007 $ 4.61 December 31, 2020 Three Months Ended Nine Months Ended Number of Shares Weighted-Average Grant Date Fair Value Per Share Number of Shares Weighted-Average Grant Date Fair Value Per Share Balance at beginning of period 812,180 $ 4.00 — $ — Granted — $ — 816,180 $ 4.00 Vested — $ — (4,000) $ 4.00 Canceled (6,855) $ 4.00 (6,855) $ 4.00 Balance at end of period 805,325 $ 4.00 805,325 $ 4.00 |
Stock-based compensation expense | The accompanying unaudited condensed consolidated statement of operations and comprehensive loss includes stock-based compensation expense for the periods presented as follows (in thousands) : Three Months Ended December 31, Nine Months Ended December 31, 2021 2020 2021 2020 Cost of revenue $ 52 $ 50 $ 118 $ 78 Research and development 145 158 383 260 Sales and marketing 88 45 159 61 General and administrative 563 452 1,196 994 Total $ 848 $ 705 $ 1,856 $ 1,393 |
Unrecognized stock-based compensation | Unrecognized stock-based compensation expense as of dates presented was as follows (in thousands) : December 31, 2021 December 31, 2020 Unrecognized Expense Average Expected Recognition Period (in years) Unrecognized Expense Average Expected Recognition Period (in years) Stock options $ 1,531 2.23 $ 54 0.67 Restricted stock 3,117 1.74 2,687 1.87 Total $ 4,648 1.90 $ 2,741 1.85 |
Business and Basis of Present_3
Business and Basis of Presentation (Details) | Jul. 16, 2021USD ($) | Feb. 12, 2020$ / sharesshares | Dec. 31, 2021USD ($)shares | Sep. 30, 2021USD ($)$ / sharesshares | Aug. 31, 2021USD ($) | Jul. 31, 2021USD ($) | Jun. 30, 2021USD ($) | Mar. 31, 2021USD ($)shares | Dec. 31, 2020USD ($)shares | Dec. 31, 2021USD ($)shares | Sep. 30, 2021USD ($)$ / sharesshares | Jun. 30, 2021USD ($) | Mar. 31, 2021USD ($)shares | Dec. 31, 2020USD ($)shares | Sep. 30, 2020USD ($)shares | Dec. 31, 2021USD ($)segmentshares | Dec. 31, 2020USD ($)shares | Oct. 04, 2021USD ($)$ / sharesshares | Mar. 31, 2020shares | Feb. 11, 2020shares |
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Merger conversion rate (in shares) | shares | 0.08289152527 | |||||||||||||||||||
Common stock, shares issued (in shares) | shares | 4,171,571 | 53,066,922 | 40,531,996 | 53,066,922 | 40,531,996 | 53,066,922 | 50,325,662 | |||||||||||||
Common stock, forfeited and cancelled (in shares) | shares | 682,699 | |||||||||||||||||||
Shares issued under company plans (in shares) | shares | 2,461,923 | 2,957,904 | 2,506,531 | 2,543,125 | 2,320,318 | 2,957,904 | 2,506,531 | 2,543,125 | 2,320,318 | 2,327,423 | 2,957,904 | 2,320,318 | 2,458,091 | |||||||
Number of Shares | shares | 15,461 | 2,742,065 | 2,742,065 | 2,742,065 | 186,535 | |||||||||||||||
Conversion price per share on convertible note payable (in dollars per share) | $ / shares | $ 5.12 | |||||||||||||||||||
Number of common stock shares converted per preferred share (in shares) | shares | 3,120,000 | |||||||||||||||||||
Net cash used in operating activities | $ (13,910,000) | $ (7,964,000) | ||||||||||||||||||
Proceeds from issuance of common stock, net | $ 50,900,000 | 49,773,000 | 13,646,000 | |||||||||||||||||
Restricted cash | $ 575,000 | $ 575,000 | 575,000 | |||||||||||||||||
Restricted cash in current asset | 500,000 | $ 0 | 500,000 | $ 0 | 500,000 | |||||||||||||||
Cash and cash equivalents | 40,467,000 | 9,500,000 | 40,467,000 | 9,500,000 | 40,467,000 | |||||||||||||||
Provision for doubtful accounts | 0 | 0 | 110,000 | |||||||||||||||||
Recovery from doubtful accounts | $ (36,000) | |||||||||||||||||||
Goodwill impairment charges | 0 | 0 | 0 | 0 | ||||||||||||||||
Impairment of intangible assets | 0 | 0 | 0 | 0 | ||||||||||||||||
Revenue from product and license fees | 4,604,000 | 2,013,000 | 19,123,000 | 10,271,000 | ||||||||||||||||
Term of cooperation and development agreement. | 3 years | |||||||||||||||||||
Cumulative effect of government rate change | (83,000) | $ 505,000 | 423,000 | |||||||||||||||||
Grant reimbursement | $ 80,000 | $ 47,000 | $ 151,000 | $ 353,000 | ||||||||||||||||
Number of anti-dilutive shares (in shares) | shares | 6,947,976 | 3,285,058 | 6,947,976 | 3,285,058 | ||||||||||||||||
Number of reportable segments | segment | 1 | |||||||||||||||||||
Yaskawa | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Conversion price per share on convertible note payable (in dollars per share) | $ / shares | $ 5.12 | $ 5 | $ 5 | $ 5 | ||||||||||||||||
Yaskawa Note | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Accrued interest on promissory note | 0 | 523,000 | $ 0 | 523,000 | $ 0 | |||||||||||||||
Yaskawa Note | Yaskawa | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Principal and unpaid interest of convertible note | $ 15,600,000 | |||||||||||||||||||
Principal amount of long term loan facility | 15,000,000 | 15,000,000 | 15,000,000 | |||||||||||||||||
Accrued interest on promissory note | 600,000 | $ 600,000 | $ 600,000 | |||||||||||||||||
Number of common stock shares converted per preferred share (in shares) | shares | 3,120,000 | |||||||||||||||||||
Transphorm Technology 2007 Stock Plan and 2015 Equity Incentive Plan | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Shares issued under company plans (in shares) | shares | 29,703,285 | |||||||||||||||||||
Series 1 Preferred Stock | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Convertible preferred stock, shares outstanding (in shares) | shares | 51,680,254 | |||||||||||||||||||
Convertible preferred stock, shares issued (in shares) | shares | 51,680,254 | |||||||||||||||||||
Share conversion in connection with the Merger (in shares) | shares | 12,433,953 | |||||||||||||||||||
Series 2 Preferred Stock | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Convertible preferred stock, shares outstanding (in shares) | shares | 38,760,190 | |||||||||||||||||||
Convertible preferred stock, shares issued (in shares) | shares | 38,760,190 | |||||||||||||||||||
Conversion of stock (in shares) | shares | 7,499,996 | |||||||||||||||||||
Series 3 Preferred Stock | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Convertible preferred stock, shares outstanding (in shares) | shares | 31,850,304 | |||||||||||||||||||
Convertible preferred stock, shares issued (in shares) | shares | 31,850,304 | |||||||||||||||||||
Conversion of stock (in shares) | shares | 4,000,000 | |||||||||||||||||||
Common Stock | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Price per share (in dollars per share) | $ / shares | $ 4 | |||||||||||||||||||
Share conversion in connection with the Merger (in shares) | shares | 3,120,000 | 3,120,000 | ||||||||||||||||||
Yaskawa | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Letter of intent for development activities | $ 4,000,000 | |||||||||||||||||||
Proceeds from collaborators | $ 750,000 | 1,000,000 | ||||||||||||||||||
Revenue recognized for collaboration development activities | 375,000 | $ 375,000 | $ 333,000 | 333,000 | $ 333,000 | $ 375,000 | $ 375,000 | $ 333,000 | 333,000 | $ 333,000 | ||||||||||
Transphorm Technology | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Share conversion in connection with the Merger (in shares) | shares | 28,105,520 | |||||||||||||||||||
Other Assets | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Restricted cash | 75,000 | 75,000 | 75,000 | 75,000 | $ 75,000 | |||||||||||||||
License and Service | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Revenue from product and license fees | $ 8,000,000 | $ 0 | $ 0 | $ 8,000,000 | $ 5,000,000 | |||||||||||||||
Stock options | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Number of anti-dilutive shares (in shares) | shares | 2,957,904 | 2,320,318 | 2,957,904 | 2,320,318 | ||||||||||||||||
Warrant | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Number of anti-dilutive shares (in shares) | shares | 2,742,065 | 159,415 | 2,742,065 | 159,415 | ||||||||||||||||
Restricted Stock Awards (RSA) | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Number of anti-dilutive shares (in shares) | shares | 1,248,007 | 805,325 | 1,248,007 | 805,325 | ||||||||||||||||
Minimum | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Property and equipment, estimated useful life | 3 years | |||||||||||||||||||
Intangible assets, estimated useful life | 3 years | |||||||||||||||||||
Award vesting period | 1 year | |||||||||||||||||||
Maximum | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Property and equipment, estimated useful life | 7 years | |||||||||||||||||||
Intangible assets, estimated useful life | 10 years | |||||||||||||||||||
Award vesting period | 4 years | |||||||||||||||||||
JAPAN | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Cash and cash equivalents | $ 65,000 | $ 444,000 | $ 65,000 | $ 444,000 | $ 65,000 | |||||||||||||||
Percentage of cash and cash equivalents in foreign subsidiary | 0.20% | 4.70% | 0.20% | 4.70% | 0.20% | |||||||||||||||
Revenue from product and license fees | $ 9,000 | $ 392,000 | $ 506,000 | $ 702,000 | ||||||||||||||||
UNITED STATES | ||||||||||||||||||||
Cash and Cash Equivalents [Line Items] | ||||||||||||||||||||
Revenue from product and license fees | $ 4,600,000 | $ 1,600,000 | $ 18,600,000 | $ 9,600,000 |
Nexperia Arrangement (Details)
Nexperia Arrangement (Details) - USD ($) | Jul. 16, 2021 | Apr. 04, 2018 | Jun. 30, 2020 | Dec. 31, 2019 | Oct. 31, 2019 | Apr. 30, 2019 | Jan. 31, 2019 | Oct. 31, 2018 | Jul. 31, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2018 | Jun. 30, 2021 | May 18, 2021 | Mar. 01, 2021 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||
License fees | $ 9,000,000 | $ 5,000,000 | $ 3,000,000 | $ 3,000,000 | $ 3,000,000 | $ 9,000,000 | ||||||||||||
Revenue from product and license fees | $ 4,604,000 | $ 2,013,000 | $ 19,123,000 | $ 10,271,000 | ||||||||||||||
License and Service | ||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||
Revenue from product and license fees | $ 8,000,000 | $ 0 | $ 0 | $ 8,000,000 | $ 5,000,000 | |||||||||||||
Series 3 Preferred Stock | ||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||
Issuance of preferred stock | 16,000,000 | |||||||||||||||||
Tranche A Loan | ||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||
Long-term loan facility | 5,000,000 | |||||||||||||||||
Reduction of debt | $ 5,000,000 | |||||||||||||||||
Proceeds from issuance of debt | $ 5,000,000 | |||||||||||||||||
Tranche B Loan | ||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||
Long-term loan facility | 10,000,000 | $ 8,000,000 | 8,000,000 | $ 8,000,000 | $ 10,000,000 | |||||||||||||
Proceeds from issuance of debt | $ 8,000,000 | |||||||||||||||||
Tranche C Loan | ||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||
Revolving loan | $ 10,000,000 | $ 10,000,000 | ||||||||||||||||
Proceeds from issuance of debt | $ 10,000,000 | |||||||||||||||||
Tranche B-1 Loan | ||||||||||||||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||||||||||||
Long-term loan facility | $ 2,000,000 | $ 2,000,000 | $ 2,000,000 | |||||||||||||||
Proceeds from issuance of debt | $ 2,000,000 | |||||||||||||||||
Repayment of Nexperia debt | $ 8,000,000 |
Fair Value Measurements - Fair
Fair Value Measurements - Fair value hierarchy (Details) - Fair Value, Recurring - USD ($) $ in Thousands | Dec. 31, 2021 | Mar. 31, 2021 |
Level 1 | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Promissory note | $ 0 | $ 0 |
Level 2 | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Promissory note | 0 | 0 |
Level 3 | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Promissory note | $ 0 | $ 16,128 |
Fair Value Measurements - Chang
Fair Value Measurements - Changes in level 3 inputs (Details) - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended |
Dec. 31, 2021 | Mar. 31, 2021 | |
Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward] | ||
Fair value at beginning of period | $ 16,128 | $ 13,885 |
Interest expense accrued | 77 | 150 |
Increase in fair value | (605) | 2,093 |
Conversion | (15,600) | |
Fair value at period end | $ 0 | $ 16,128 |
Fair Value Measures - Narrative
Fair Value Measures - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Oct. 04, 2021 | Mar. 31, 2021 | |
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Number of common stock shares converted per preferred share (in shares) | 3,120,000 | |||||
Interest expense | $ 187 | $ 191 | $ 611 | $ 571 | ||
Changes in fair value of promissory note | 0 | 973 | 605 | (1,394) | ||
Yaskawa Note | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Accrued interest on promissory note | 0 | 0 | $ 523 | |||
Interest expense | 3 | 38 | 77 | 113 | ||
Changes in fair value of promissory note | $ (973) | (605) | $ 1,400 | |||
Yaskawa Note | Yaskawa | ||||||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||||||
Principal and unpaid interest of convertible note | $ 15,600 | |||||
Principal amount of long term loan facility | 15,000 | 15,000 | ||||
Accrued interest on promissory note | $ 600 | $ 600 | ||||
Number of common stock shares converted per preferred share (in shares) | 3,120,000 |
Fair Value Measurements - Fai_2
Fair Value Measurements - Fair value measurement inputs (Details) | Dec. 31, 2021$ / shares | Mar. 31, 2021$ / shares |
Stock price (in usd per share) | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Promissory note, fair value measurement inputs | 0 | 3.75 |
Time | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Promissory note, expected term | 1 year 6 months | |
Risk-free rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Promissory note, fair value measurement inputs | 0 | 0.0012 |
Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Promissory note, fair value measurement inputs | 0 | 0.506 |
Concentration of Credit Risk _3
Concentration of Credit Risk and Significant Customers (Details) - Customer Concentration Risk | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2021 | |
Revenue | Customer A | |||||
Concentration Risk [Line Items] | |||||
Percentage of revenue or accounts receivable | 10.90% | 23.80% | 49.80% | 62.60% | |
Revenue | Customer B | |||||
Concentration Risk [Line Items] | |||||
Percentage of revenue or accounts receivable | 21.30% | 43.90% | 15.70% | 26.60% | |
Revenue | Customer C | |||||
Concentration Risk [Line Items] | |||||
Percentage of revenue or accounts receivable | 41.20% | 16.10% | |||
Accounts Receivable | Customer A | |||||
Concentration Risk [Line Items] | |||||
Percentage of revenue or accounts receivable | 15.30% | 31.10% | |||
Accounts Receivable | Customer B | |||||
Concentration Risk [Line Items] | |||||
Percentage of revenue or accounts receivable | 21.10% | 33.90% | |||
Accounts Receivable | Customer C | |||||
Concentration Risk [Line Items] | |||||
Percentage of revenue or accounts receivable | 39.70% | ||||
Accounts Receivable | Customer D | |||||
Concentration Risk [Line Items] | |||||
Percentage of revenue or accounts receivable | 10.00% |
Inventory (Details)
Inventory (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2021 | |
Inventory Disclosure [Abstract] | |||||
Raw materials | $ 2,423 | $ 2,423 | $ 626 | ||
Work in process | 2,191 | 2,191 | 1,054 | ||
Finished goods | 1,342 | 1,342 | 543 | ||
Total | 5,956 | 5,956 | $ 2,223 | ||
Inventory write-off | $ 8 | $ 161 | $ 202 | $ 266 |
Debts - Additional information
Debts - Additional information (Details) | Oct. 04, 2021USD ($)$ / sharesshares | Jul. 16, 2021USD ($) | Feb. 12, 2020shares$ / shares | Dec. 31, 2021USD ($) | Oct. 31, 2021USD ($)shares | Sep. 30, 2021USD ($)$ / shares | Jul. 31, 2021USD ($) | Jun. 30, 2021USD ($) | Mar. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2021USD ($) | Sep. 30, 2021USD ($)$ / shares | Jun. 30, 2021USD ($) | Mar. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Mar. 31, 2021USD ($) | May 18, 2021USD ($) | Mar. 01, 2021USD ($) | Dec. 31, 2019USD ($) | Jul. 31, 2019USD ($) | Mar. 31, 2019USD ($) | Apr. 04, 2018USD ($) | Oct. 31, 2017USD ($) |
Line of Credit Facility [Line Items] | |||||||||||||||||||||||||
Aggregate principal amount of loans outstanding | $ 12,368,000 | $ 12,368,000 | $ 12,368,000 | ||||||||||||||||||||||
Interest expense accrued | 77,000 | $ 150,000 | |||||||||||||||||||||||
Outstanding balance on line of credit facility | 12,400,000 | $ 10,200,000 | 12,400,000 | $ 10,200,000 | 12,400,000 | 10,200,000 | |||||||||||||||||||
Changes in fair value of promissory note | 0 | $ 973,000 | 605,000 | $ (1,394,000) | |||||||||||||||||||||
Conversion price per share on convertible note payable (in dollars per share) | $ / shares | $ 5.12 | ||||||||||||||||||||||||
Other Nonoperating Income (Expense) | (1,503,000) | (571,000) | (3,502,000) | (1,626,000) | |||||||||||||||||||||
Interest expense | 187,000 | 191,000 | 611,000 | 571,000 | |||||||||||||||||||||
Number of common stock shares converted per preferred share (in shares) | shares | 3,120,000 | ||||||||||||||||||||||||
Term of cooperation and development agreement. | 3 years | ||||||||||||||||||||||||
Accrued and unpaid interest on promissory note | $ 600,000 | ||||||||||||||||||||||||
Yaskawa | |||||||||||||||||||||||||
Line of Credit Facility [Line Items] | |||||||||||||||||||||||||
Conversion price per share on convertible note payable (in dollars per share) | $ / shares | $ 5 | $ 5.12 | $ 5 | $ 5 | |||||||||||||||||||||
Number of shares issued | shares | 3,120,000 | ||||||||||||||||||||||||
Warrant to purchase shares issued, number of shares | $ 650,000 | $ 650,000 | $ 650,000 | ||||||||||||||||||||||
Exercise price (in usd per share) | $ / shares | $ 6 | $ 6 | $ 6 | ||||||||||||||||||||||
Exercisable period of warrants (in years) | 3 years | 3 years | 3 years | ||||||||||||||||||||||
Accounts Payable and Accrued Liabilities | |||||||||||||||||||||||||
Line of Credit Facility [Line Items] | |||||||||||||||||||||||||
Interest expense | 0 | 153,000 | 316,000 | 915,000 | |||||||||||||||||||||
Yaskawa | |||||||||||||||||||||||||
Line of Credit Facility [Line Items] | |||||||||||||||||||||||||
Letter of intent for development activities | $ 4,000,000 | ||||||||||||||||||||||||
Proceeds from collaborators | $ 750,000 | 1,000,000 | |||||||||||||||||||||||
Revenue recognized for collaboration development activities | 375,000 | $ 375,000 | $ 333,000 | 333,000 | $ 333,000 | 375,000 | $ 375,000 | $ 333,000 | 333,000 | 333,000 | |||||||||||||||
Loan and Security Agreement (LSA) | |||||||||||||||||||||||||
Line of Credit Facility [Line Items] | |||||||||||||||||||||||||
Long-term loan facility | $ 15,000,000 | ||||||||||||||||||||||||
Aggregate principal amount of loans outstanding | $ 0 | 10,000,000 | 0 | 10,000,000 | 0 | 10,000,000 | |||||||||||||||||||
Tranche A Loan | |||||||||||||||||||||||||
Line of Credit Facility [Line Items] | |||||||||||||||||||||||||
Long-term loan facility | 5,000,000 | ||||||||||||||||||||||||
Tranche B Loan | |||||||||||||||||||||||||
Line of Credit Facility [Line Items] | |||||||||||||||||||||||||
Long-term loan facility | $ 8,000,000 | $ 8,000,000 | $ 10,000,000 | $ 8,000,000 | $ 8,000,000 | 10,000,000 | |||||||||||||||||||
Tranche B-1 Loan | |||||||||||||||||||||||||
Line of Credit Facility [Line Items] | |||||||||||||||||||||||||
Long-term loan facility | $ 2,000,000 | $ 2,000,000 | $ 2,000,000 | ||||||||||||||||||||||
Repayment of Nexperia debt | $ 8,000,000 | ||||||||||||||||||||||||
Tranche C Note | |||||||||||||||||||||||||
Line of Credit Facility [Line Items] | |||||||||||||||||||||||||
Long-term loan facility | 12,000,000 | ||||||||||||||||||||||||
Revolving loan | $ 10,000,000 | ||||||||||||||||||||||||
Interest rate per annum | 6.00% | ||||||||||||||||||||||||
Interest expense accrued | $ 184,000 | 153,000 | $ 534,000 | 458,000 | |||||||||||||||||||||
Yaskawa Note | |||||||||||||||||||||||||
Line of Credit Facility [Line Items] | |||||||||||||||||||||||||
Interest rate per annum | 1.00% | 1.00% | 1.00% | 1.00% | |||||||||||||||||||||
Changes in fair value of promissory note | (973,000) | $ (605,000) | 1,400,000 | ||||||||||||||||||||||
Unsecured subordinated convertible promissory note | $ 0 | $ 15,600,000 | $ 15,000,000 | 15,523,000 | $ 0 | $ 15,000,000 | 15,523,000 | 0 | 15,523,000 | $ 15,000,000 | |||||||||||||||
Maximum number of shares of common stock issuable (in shares) | shares | 3,076,171 | ||||||||||||||||||||||||
Interest expense | 3,000 | $ 38,000 | 77,000 | $ 113,000 | |||||||||||||||||||||
Accrued interest on promissory note | 0 | $ 523,000 | 0 | $ 523,000 | 0 | $ 523,000 | |||||||||||||||||||
Yaskawa Note | Yaskawa | |||||||||||||||||||||||||
Line of Credit Facility [Line Items] | |||||||||||||||||||||||||
Principal and unpaid interest of convertible note | $ 15,600,000 | ||||||||||||||||||||||||
Number of shares issued | shares | 3,120,000 | ||||||||||||||||||||||||
Other Nonoperating Income (Expense) | 1,200,000 | 1,200,000 | |||||||||||||||||||||||
Principal amount of long term loan facility | 15,000,000 | 15,000,000 | 15,000,000 | ||||||||||||||||||||||
Accrued interest on promissory note | $ 600,000 | $ 600,000 | $ 600,000 | ||||||||||||||||||||||
Number of common stock shares converted per preferred share (in shares) | shares | 3,120,000 |
Debts - Notes payable (Details)
Debts - Notes payable (Details) - Yaskawa Note - USD ($) $ in Thousands | Dec. 31, 2021 | Oct. 31, 2021 | Sep. 30, 2021 | Mar. 31, 2021 | Oct. 31, 2017 |
Line of Credit Facility [Line Items] | |||||
Interest rate per annum | 1.00% | 1.00% | |||
Unsecured subordinated convertible promissory note | $ 0 | $ 15,600 | $ 15,000 | $ 15,523 | $ 15,000 |
Promissory note | $ 0 | $ 16,128 |
Debts - Maturities schedule (De
Debts - Maturities schedule (Details) $ in Thousands | Dec. 31, 2021USD ($) |
Debt Disclosure [Abstract] | |
2022 | $ 368 |
2023 | 0 |
2024 | 12,000 |
Total | $ 12,368 |
Investment in Aizu Fujitsu Se_3
Investment in Aizu Fujitsu Semiconductor Wafer Solution Limited ("AFSW") - Narrative (Details) $ in Thousands | Aug. 01, 2021JPY (¥) | Jul. 31, 2021 | Dec. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Mar. 31, 2021USD ($) | Apr. 01, 2020 | Mar. 31, 2020USD ($) |
Joint Venture Company In Singapore | |||||||
Variable Interest Entity [Line Items] | |||||||
Ownership percentage | 75.00% | ||||||
GaNovation | Aizu Fujitsu Semiconductor Wafer Solution Limited (AFSW) | |||||||
Variable Interest Entity [Line Items] | |||||||
Percentage of voting interest acquired | 100.00% | ||||||
Aizu Fajitsu Semiconductor Wafer Solution Limited | |||||||
Variable Interest Entity [Line Items] | |||||||
Ownership percentage in entity | 25.00% | 49.00% | 49.00% | ||||
Gain on termination of JVA and settlement of obligation | $ 1,500 | ||||||
Additional financial support provided to investment | 3,765 | $ 5,800 | $ 6,768 | ||||
Unfunded commitment | $ 61 | $ (1,866) | $ (1,546) | ||||
Aizu Fajitsu Semiconductor Wafer Solution Limited | GaNovation | |||||||
Variable Interest Entity [Line Items] | |||||||
Percentage of ownership acquired | 49.00% | ||||||
Payment for acquisition | ¥ | ¥ 1 | ||||||
Fujitsu Semiconductor Limited | |||||||
Variable Interest Entity [Line Items] | |||||||
Purchase of additional interest | 51.00% |
Investment in Aizu Fujitsu Se_4
Investment in Aizu Fujitsu Semiconductor Wafer Solution Limited ("AFSW") - Income statement information (Details) - Aizu Fajitsu Semiconductor Wafer Solution Limited - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2021 | |
Summary of Variable Interest Entities [Roll Forward] | |||
Beginning balance | $ (1,866) | $ (1,546) | $ (1,546) |
Investment | 3,765 | $ 5,800 | 6,768 |
Loss | (3,294) | (6,885) | |
Gain | 1,455 | 0 | |
Effect of exchange rate change | 1 | (203) | |
Ending balance | $ 61 | $ (1,866) |
Investment in Aizu Fujitsu Se_5
Investment in Aizu Fujitsu Semiconductor Wafer Solution Limited ("AFSW") - Summarized financial information (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2021 | |
Variable Interest Entity [Line Items] | |||||
Current assets | $ 50,661 | $ 50,661 | $ 14,294 | ||
Other current liabilities | 0 | 0 | 1,866 | ||
Aizu Fajitsu Semiconductor Wafer Solution Limited | |||||
Variable Interest Entity [Line Items] | |||||
Current assets | 1,844 | 1,844 | 932 | ||
Long-term assets | 5,152 | 5,152 | 5,330 | ||
Other current liabilities | 3,494 | 3,494 | 2,200 | ||
Net deficit | (799) | (799) | (31,471) | ||
Variable Interest Entity, Measure of Activity [Abstract] | |||||
Sales | 2,262 | $ 698 | 5,957 | $ 1,728 | |
Gross loss | (2,338) | (2,896) | (7,094) | (9,214) | |
Net loss | (2,848) | $ (3,303) | (9,085) | $ (11,057) | |
Fujitsu Semiconductor Limited | Aizu Fajitsu Semiconductor Wafer Solution Limited | |||||
Variable Interest Entity [Line Items] | |||||
Due to controlling owner | 3,707 | 3,707 | 22,354 | ||
Transphorm, Inc. | Aizu Fajitsu Semiconductor Wafer Solution Limited | |||||
Variable Interest Entity [Line Items] | |||||
Due to Transphorm | $ 594 | $ 594 | $ 13,179 |
Commitment and Contingencies -
Commitment and Contingencies - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||
Dec. 31, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | ||||||
Commitment to acquire equipment and services | $ 7,400 | $ 7,400 | ||||
Cumulative purchases made to date | 7,200 | 7,200 | ||||
Reimbursement received from government agency | 119 | 347 | ||||
Amount purchased | $ 270 | |||||
Remaining accounts payable to vendors | 135 | $ 124 | 135 | |||
Contract for epiwafer technology | $ 900 | |||||
Option in addition to contract for epiwafer technology | $ 500 | |||||
Payments Received On Government Contracts | 2 | 5 | ||||
Rent expense | 196 | $ 237 | 661 | $ 659 | ||
Rental income from noncancelable sublease | 0 | $ 45 | 0 | $ 136 | ||
Future minimum rental payments to be received under sublease | $ 0 | $ 0 |
Commitment and Contingencies _2
Commitment and Contingencies - Operating lease maturity schedule (Details) $ in Thousands | Dec. 31, 2021USD ($) |
Commitments and Contingencies Disclosure [Abstract] | |
2022 | $ 177 |
2023 | 697 |
2024 | 666 |
Thereafter | 156 |
Total | $ 1,696 |
Stockholders' Equity (Deficit_2
Stockholders' Equity (Deficit) - Narrative (Details) $ / shares in Units, $ in Thousands | Dec. 07, 2021USD ($)$ / sharesshares | Nov. 09, 2021USD ($)$ / sharesshares | Oct. 04, 2021$ / sharesshares | Aug. 13, 2021USD ($)$ / sharesshares | Mar. 31, 2021USD ($)$ / sharesshares | Dec. 23, 2020USD ($)$ / sharesshares | Feb. 12, 2020$ / sharesshares | Oct. 31, 2021shares | Apr. 30, 2021USD ($)shares | Feb. 27, 2020USD ($)$ / sharesshares | Jan. 10, 2022$ / shares | Dec. 31, 2021$ / sharesshares | Nov. 08, 2021segment$ / sharesshares | Nov. 05, 2021$ / sharesshares | Sep. 30, 2021$ / sharesshares | Dec. 31, 2020shares | Sep. 30, 2020shares | Mar. 31, 2020shares | Feb. 11, 2020shares | Dec. 31, 2019$ / sharesshares |
Class of Stock [Line Items] | ||||||||||||||||||||
Common stock, shares issued (in shares) | 40,531,996 | 4,171,571 | 53,066,922 | 50,325,662 | ||||||||||||||||
Common stock, shares outstanding (in shares) | 40,531,996 | 4,171,571 | 53,066,922 | 50,325,662 | ||||||||||||||||
Shares issued in connection with the Reverse Merger (in shares) | 1,650,000 | |||||||||||||||||||
Total common and preferred stock authorized for issuance (in shares) | 755,000,000 | |||||||||||||||||||
Common stock, shares authorized (in shares) | 750,000,000 | 750,000,000 | ||||||||||||||||||
Common stock, par value (in usd per share) | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||||||
Par value per share (in usd per share) | $ / shares | $ 0.0001 | |||||||||||||||||||
Preferred stock, shares issued (in shares) | 0 | |||||||||||||||||||
Preferred stock, shares outstanding (in shares) | 0 | |||||||||||||||||||
Yaskawa | ||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||
Number of shares converted from debt | 3,120,000 | |||||||||||||||||||
Exercise price (in usd per share) | $ / shares | $ 6 | $ 6 | ||||||||||||||||||
Yaskawa Note | Yaskawa | ||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||
Number of shares converted from debt | 3,120,000 | |||||||||||||||||||
Common Stock | ||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||
Common stock, shares outstanding (in shares) | 40,531,996 | 53,066,922 | 41,664,020 | 40,278,496 | 35,266,496 | 35,135,520 | ||||||||||||||
Number of shares sold in private placement offering (in shares) | 97,099 | |||||||||||||||||||
Price per share (in dollars per share) | $ / shares | $ 4 | |||||||||||||||||||
Aggregate gross proceeds from closing of offering | $ | $ 500 | |||||||||||||||||||
Private Placement | ||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||
Placement agent fees and closing expenses | $ | $ 286 | $ 840 | $ 22 | $ 1,800 | ||||||||||||||||
Private Placement | Common Stock | ||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||
Number of shares sold in private placement offering (in shares) | 1,673,152 | 6,600,000 | 1,000,000 | 250,000 | 5,000,000 | 5,380,000 | ||||||||||||||
Price per share (in dollars per share) | $ / shares | $ 7.71 | $ 5 | $ 5 | $ 4 | $ 3 | $ 4 | ||||||||||||||
Aggregate gross proceeds from closing of offering | $ | $ 12,900 | $ 33,000 | $ 5,000 | $ 1,000 | $ 15,000 | $ 21,500 | ||||||||||||||
Placement agent fees and closing expenses | $ | $ 50 | $ 1,400 | ||||||||||||||||||
Exercise price (in usd per share) | $ / shares | $ 9.25 | $ 6 | $ 6 | $ 6 | $ 3.30 | $ 6 | ||||||||||||||
Private Placement | Warrant | ||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||
Placement agent fees and closing expenses | $ | $ 223 | |||||||||||||||||||
Number of common stock issuable from warrants (in shares) | 348,649 | 416,667 | 650,000 | 209,000 | 150,000 | 958,334 | ||||||||||||||
Second Investment Period | Common Stock | ||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||
Number of shares sold in private placement offering (in shares) | 3,299,999 | |||||||||||||||||||
Price per share (in dollars per share) | $ / shares | $ 5 | |||||||||||||||||||
Number of common stock issuable from warrants (in shares) | 687,501 | |||||||||||||||||||
Series 1 Preferred Stock | ||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||
Convertible preferred stock, shares issued (in shares) | 51,680,254 | |||||||||||||||||||
Convertible preferred stock, shares outstanding (in shares) | 51,680,254 | |||||||||||||||||||
Common stock, shares issued (in shares) | 12,433,953 | |||||||||||||||||||
Common stock, shares outstanding (in shares) | 12,433,953 | |||||||||||||||||||
Series 2 Preferred Stock | ||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||
Convertible preferred stock, shares issued (in shares) | 38,760,190 | |||||||||||||||||||
Convertible preferred stock, shares outstanding (in shares) | 38,760,190 | |||||||||||||||||||
Common stock, shares issued (in shares) | 7,499,996 | |||||||||||||||||||
Common stock, shares outstanding (in shares) | 7,499,996 | |||||||||||||||||||
Series 3 Preferred Stock | ||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||
Convertible preferred stock, shares issued (in shares) | 31,850,304 | |||||||||||||||||||
Convertible preferred stock, shares outstanding (in shares) | 31,850,304 | |||||||||||||||||||
Common stock, shares issued (in shares) | 4,000,000 | |||||||||||||||||||
Common stock, shares outstanding (in shares) | 4,000,000 | |||||||||||||||||||
Common Stock | ||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||
Shares redeemed (in shares) | 52,733 | |||||||||||||||||||
Common stock, shares authorized (in shares) | 750,000,000 | |||||||||||||||||||
Common Stock | Subsequent Event | ||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||
Exercise price (in usd per share) | $ / shares | $ 3.30 | |||||||||||||||||||
Common Stock | Second Investment Period | ||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||
Required notice period of change in control (in days) | segment | 10 | |||||||||||||||||||
Preferred Stock | ||||||||||||||||||||
Class of Stock [Line Items] | ||||||||||||||||||||
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Stockholders' Equity (Deficit_3
Stockholders' Equity (Deficit) - Reserved common stock (Details) | Dec. 31, 2021shares |
Class of Stock [Line Items] | |
Common stock reserved for issuance (in shares) | 9,764,014 |
Warrant | |
Class of Stock [Line Items] | |
Common stock reserved for issuance (in shares) | 2,742,065 |
Stock options | |
Class of Stock [Line Items] | |
Common stock reserved for issuance (in shares) | 7,021,949 |
Stockholders' Equity (Deficit_4
Stockholders' Equity (Deficit) - Warrants (Details) - $ / shares | Jan. 10, 2022 | Jan. 05, 2022 | Dec. 31, 2021 | Feb. 12, 2020 | Feb. 11, 2020 |
Class of Stock [Line Items] | |||||
Number of shares (in shares) | 2,742,065 | 15,461 | 186,535 | ||
Common Stock | Subsequent Event | |||||
Class of Stock [Line Items] | |||||
Exercise price (in usd per share) | $ 3.30 | ||||
Issuance of common stock for exercise of warrants (in shares) | 82,500 | 13,028 | |||
5 years after an initial public offering of the Company | |||||
Class of Stock [Line Items] | |||||
Exercise price (in usd per share) | $ 34.74 | ||||
Number of shares (in shares) | 6,046 | ||||
5 years after an initial public offering of the Company | |||||
Class of Stock [Line Items] | |||||
Exercise price (in usd per share) | $ 54.41 | ||||
Number of shares (in shares) | 3,369 | ||||
December 23, 2025 | |||||
Class of Stock [Line Items] | |||||
Exercise price (in usd per share) | $ 3.30 | ||||
Number of shares (in shares) | 150,000 | ||||
August 13, 2024 | |||||
Class of Stock [Line Items] | |||||
Exercise price (in usd per share) | $ 6 | ||||
Number of shares (in shares) | 209,000 | ||||
Expiration Date 5 | |||||
Class of Stock [Line Items] | |||||
Exercise price (in usd per share) | $ 6 | ||||
Number of shares (in shares) | 650,000 | ||||
Expiration Date 6 | |||||
Class of Stock [Line Items] | |||||
Exercise price (in usd per share) | $ 6 | ||||
Number of shares (in shares) | 958,334 | ||||
Expiration Date 7 | |||||
Class of Stock [Line Items] | |||||
Exercise price (in usd per share) | $ 6 | ||||
Number of shares (in shares) | 416,667 | ||||
Expiration Date 8 | |||||
Class of Stock [Line Items] | |||||
Exercise price (in usd per share) | $ 9.25 | ||||
Number of shares (in shares) | 348,649 |
Stock-Based Compensation (Detai
Stock-Based Compensation (Details) - shares | Apr. 01, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Dec. 31, 2021 | Sep. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2020 | Feb. 12, 2020 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Options outstanding under The 2020 Plan (in shares) | 2,320,318 | 2,327,423 | 2,957,904 | 2,506,531 | 2,543,125 | 2,320,318 | 2,327,423 | 2,957,904 | 2,320,318 | 2,458,091 | 2,461,923 | |
Common stock reserved for issuance (in shares) | 9,764,014 | 9,764,014 | ||||||||||
Percentage of outstanding shares | 5.00% | 5.00% | ||||||||||
Maximum | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Award vesting period | 4 years | |||||||||||
Restricted Stock Awards (RSA) | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Restricted stock granted (in shares) | 12,000 | 123,501 | ||||||||||
Vesting of restricted stock units (in shares) | 98,450 | |||||||||||
Restricted Stock Units (RSUs) | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Restricted stock granted (in shares) | 307,640 | 35,000 | 137,452 | 0 | 816,180 | 342,640 | 816,180 | |||||
Vesting of restricted stock units (in shares) | 9,750 | 0 | 4,000 | 12,750 | 4,000 | |||||||
Percentage vesting | 25.00% | |||||||||||
Award vesting period | 4 years | 3 years | ||||||||||
Restricted Stock Units (RSUs) | Period 1 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Percentage vesting | 33.33% | |||||||||||
Restricted Stock Units (RSUs) | Period 2 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Percentage vesting | 33.33% | |||||||||||
Restricted Stock Units (RSUs) | Period 3 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Percentage vesting | 33.33% | |||||||||||
Restricted Stock Units (RSUs) | Period 4 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Percentage vesting | 25.00% | |||||||||||
Award vesting period | 1 year | |||||||||||
The 2020 Equity Incentive Plan | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Options outstanding under The 2020 Plan (in shares) | 2,957,904 | 2,957,904 | ||||||||||
Common stock reserved for issuance (in shares) | 2,816,038 | 2,816,038 | ||||||||||
Annual increase in shares available for issue (in shares) | 2,026,599 | |||||||||||
Number of shares authorized by 2020 plan (in shares) | 5,050,000 | 5,050,000 | ||||||||||
The 2020 Equity Incentive Plan | Maximum | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Annual increase in shares available for issue (in shares) | 5,000,000 | |||||||||||
Options authorized (in shares) | 2,461,923 | |||||||||||
The 2020 Equity Incentive Plan | Restricted Stock Awards (RSA) | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Equity Awards outstanding under The 2020 Plan (in shares) | 1,248,007 | 1,248,007 | ||||||||||
Transphorm Technology 2007 Stock Plan and 2015 Equity Incentive Plan | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||
Options outstanding under The 2020 Plan (in shares) | 29,703,285 | |||||||||||
Number of shares authorized by 2020 plan (in shares) | 2,588,077 | 2,588,077 |
Stock-Based Compensation - Sche
Stock-Based Compensation - Schedule of option activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||
Dec. 31, 2021 | Sep. 30, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2021 | Mar. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] | |||||||||
Beginning balance, Options outstanding (in shares) | 2,506,531 | 2,327,423 | 2,458,091 | 2,543,125 | 2,458,091 | 2,458,091 | |||
Options granted (in shares) | 473,077 | 0 | 528,077 | 0 | |||||
Options exercised (in shares) | 0 | 0 | (31,925) | (3,475) | |||||
Options cancelled (in shares) | (21,704) | (7,105) | (81,373) | (134,298) | |||||
Ending balance, Options outstanding (in shares) | 2,957,904 | 2,506,531 | 2,320,318 | 2,327,423 | 2,957,904 | 2,320,318 | 2,543,125 | ||
Exercisable at period end (in shares) | 2,227,540 | 2,267,154 | 2,227,540 | 2,267,154 | |||||
Weighted Average Exercise Price per Share | |||||||||
Beginning of period (in dollars per share) | $ 4.77 | $ 4.68 | $ 4.74 | $ 4.82 | $ 4.74 | $ 4.74 | |||
Options granted (in dollars per share) | 6.52 | 0 | 6.31 | 0 | |||||
Options exercised (in dollars per share) | 0 | 0 | 4.21 | 3.80 | |||||
Options cancelled (in dollars per share) | 9.32 | 8.96 | 7.46 | 6.01 | |||||
End of period (in dollars per share) | 5.02 | $ 4.77 | 4.67 | $ 4.68 | 5.02 | 4.67 | $ 4.82 | ||
Exercisable at end of period (in usd per share) | $ 4.61 | $ 4.70 | $ 4.61 | $ 4.70 | |||||
Weighted Average Remaining Contractual Term (in years) | |||||||||
Options outstanding, weighted average remaining contractual term (in years) | 6 years 1 month 20 days | 5 years 8 months 1 day | 5 years 11 months 1 day | 6 years 1 month 28 days | 6 years 6 months 29 days | 6 years 1 month 20 days | 5 years 11 months 1 day | 6 years 18 days | |
Options exercisable, weighted average remaining contractual term (in years) | 5 years | 5 years 10 months 9 days | 5 years | 5 years 10 months 9 days | |||||
Aggregate Intrinsic Value (in thousands) | |||||||||
Options outstanding, aggregate intrinsic value | $ 9,218 | $ 590 | $ 0 | $ 167 | $ 9,218 | $ 0 | $ 0 | $ 0 | |
Options exercisable, aggregate intrinsic value | $ 7,958 | $ 0 | $ 7,958 | $ 0 | |||||
Closing stock price (in dollars per share) | $ 8 | $ 3 | $ 8 | $ 3 |
Stock-Based Compensation - Fair
Stock-Based Compensation - Fair value assumptions (Details) - Stock options - $ / shares | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Weighted average expected life (in years) | 5 years 10 months 6 days | 5 years 10 months 17 days | ||
Risk-free interest rate | 0.0132% | 0.00% | 1.30% | 0.00% |
Expected volatility | 0.4265% | 0.00% | 42.77% | 0.00% |
Grant date fair market value (in dollars per share) | $ 6.55 | $ 0 | $ 6.34 | $ 0 |
Grant date fair value (in usd per share) | $ 3.11 | $ 0 | $ 2.99 | $ 0 |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% |
Stock-Based Compensation - Rest
Stock-Based Compensation - Restricted stock (Details) - $ / shares | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||||||
Dec. 31, 2020 | Sep. 30, 2020 | Dec. 31, 2021 | Sep. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] | |||||||||
Restricted stock canceled (in shares) | (1,520) | (6,855) | (17,280) | (6,855) | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] | |||||||||
Restricted stock cancelled (in dollars per share) | $ 3,850 | $ 4,000 | $ 3,970 | $ 4,000 | |||||
Restricted Stock Awards (RSA) | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] | |||||||||
Restricted stock granted (in shares) | 12,000 | 123,501 | |||||||
Restricted stock vested (in shares) | (98,450) | ||||||||
Restricted Stock Units (RSUs) | |||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] | |||||||||
Restricted stock at beginning of period (in shares) | 951,637 | 805,325 | 812,180 | 935,397 | 0 | ||||
Restricted stock granted (in shares) | 307,640 | 35,000 | 137,452 | 0 | 816,180 | 342,640 | 816,180 | ||
Restricted stock vested (in shares) | (9,750) | 0 | (4,000) | (12,750) | (4,000) | ||||
Restricted stock at end of period (in shares) | 805,325 | 812,180 | 1,248,007 | 951,637 | 935,397 | 805,325 | 812,180 | 1,248,007 | 805,325 |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] | |||||||||
Restricted stock at beginning of period (in dollars per share) | $ 3,960 | $ 4,000 | $ 4,000 | $ 3,960 | $ 0 | ||||
Restricted stock granted (in dollars per share) | 6,600 | 0 | 6,310 | 4,000 | |||||
Restricted stock vested (in dollars per share) | 3,750 | 0 | 3,750 | 4,000 | |||||
Restricted stock at end of period (in dollars per share) | $ 4,000 | $ 4,000 | $ 4,610 | $ 3,960 | $ 3,960 | $ 4,000 | $ 4,000 | $ 4,610 | $ 4,000 |
Stock-Based Compensation - Shar
Stock-Based Compensation - Share-based payment arrangement, expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock based compensation expense | $ 848 | $ 705 | $ 1,856 | $ 1,393 |
Cost of revenue | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock based compensation expense | 52 | 50 | 118 | 78 |
Research and development | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock based compensation expense | 145 | 158 | 383 | 260 |
Sales and marketing | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock based compensation expense | 88 | 45 | 159 | 61 |
General and administrative | ||||
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] | ||||
Stock based compensation expense | $ 563 | $ 452 | $ 1,196 | $ 994 |
Stock-Based Compensation - Unre
Stock-Based Compensation - Unrecognized stock-based compensation (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Unrecognized Expense | $ 4,648 | $ 2,741 |
Average Expected Recognition Period (in years) | 1 year 10 months 24 days | 1 year 10 months 6 days |
Stock options | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock options | $ 1,531 | $ 54 |
Average Expected Recognition Period (in years) | 2 years 2 months 23 days | 8 months 1 day |
Restricted Stock Units (RSUs) | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Restricted stock | $ 3,117 | $ 2,687 |
Average Expected Recognition Period (in years) | 1 year 8 months 26 days | 1 year 10 months 13 days |
Related Party Transactions (Det
Related Party Transactions (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2021 | |
Related Party Transaction | |||||
Accounts receivable due from related party | $ 1,800 | $ 1,800 | $ 14,100 | ||
Other Nonoperating Income (Expense) | (1,503) | $ (571) | (3,502) | $ (1,626) | |
Corporate Joint Venture | |||||
Related Party Transaction | |||||
Accounts receivable due from related party | 1,300 | 1,300 | 13,500 | ||
Corporate Joint Venture | Related Party Services | |||||
Related Party Transaction | |||||
Related party transaction expenses | 791 | 13 | 2,300 | 130 | |
Corporate Joint Venture | Research and development | |||||
Related Party Transaction | |||||
Related party transaction expenses | 102 | 152 | 401 | 674 | |
Corporate Joint Venture | Purchase of Inventory | |||||
Related Party Transaction | |||||
Related party transaction expenses | 70 | 140 | |||
Corporate Joint Venture | Consumption Tax | |||||
Related Party Transaction | |||||
Related party transaction expenses | 55 | 92 | |||
Corporate Joint Venture | Commitment For Services | |||||
Related Party Transaction | |||||
Related party transaction expenses | 124 | 11 | 221 | 14 | |
Corporate Joint Venture | Other Income | |||||
Related Party Transaction | |||||
Gain on termination of JVA and settlement of obligation | 1,500 | ||||
Noncontrolling Common Stockholder | |||||
Related Party Transaction | |||||
Accounts receivable due from related party | 5 | ||||
Accounts payable to related party | 684 | 684 | 370 | ||
Accrued royalties | 4 | ||||
Noncontrolling Common Stockholder | Nexperia | |||||
Related Party Transaction | |||||
Accounts payable to related party | 74 | 74 | 11 | ||
Noncontrolling Common Stockholder | Sale of Products | |||||
Related Party Transaction | |||||
Revenue from related parties | 12 | 19 | 152 | ||
Noncontrolling Common Stockholder | License Maintenance Fee | |||||
Related Party Transaction | |||||
Related party transaction expenses | 50 | 111 | 150 | ||
Noncontrolling Common Stockholder | Consulting Expense | |||||
Related Party Transaction | |||||
Related party transaction expenses | 176 | ||||
Common Stockholder | |||||
Related Party Transaction | |||||
Accounts receivable due from related party | 374 | 374 | $ 503 | ||
Common Stockholder | Sale of Products | |||||
Related Party Transaction | |||||
Revenue from related parties | 504 | 421 | 1,000 | 571 | |
Common Stockholder | License Maintenance Fee | |||||
Related Party Transaction | |||||
Reduction in license maintenance fees | 38 | 38 | 113 | 113 | |
Common Stockholder | License Fee Income | |||||
Related Party Transaction | |||||
Revenue from related parties | 21 | 8,500 | 5,200 | ||
Common Stockholder | Interest Expense | |||||
Related Party Transaction | |||||
Related party transaction expenses | 184 | 153 | 534 | 458 | |
Common Stockholder | Reimbursement for research and development | |||||
Related Party Transaction | |||||
Revenue from related parties | 231 | ||||
Common Stockholder | EPI Gen 4 wafer growth sales | |||||
Related Party Transaction | |||||
Revenue from related parties | $ 38 | $ 701 | |||
Yaskawa | Yaskawa Note | |||||
Related Party Transaction | |||||
Other Nonoperating Income (Expense) | 1,200 | 1,200 | |||
Yaskawa | Sale of Products | |||||
Related Party Transaction | |||||
Revenue from related parties | 1,100 | ||||
Yaskawa | Cooperation And Development Agreement | |||||
Related Party Transaction | |||||
Revenue from related parties | 375 | ||||
GaNovation | |||||
Related Party Transaction | |||||
Revenue from related parties | 251 | 405 | |||
Accounts receivable due from related party | $ 186 | $ 186 |